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ABSTRACT 
Introduction: 
AIDS was postulated initially as an infective condition  way back in 1981(Gotlieb et al). 
Worldwide there are forty million population living with Human Immunodeficiency Virus 
(HIV)/ Acquired ImmunoDeficiency Syndrome (AIDS). Within a span of  four decades, it has 
established  to become a global pandemic imposing a major threat to different walks of life. It 
has immense effect on social as well as economic perspectives of   Nations. Projections of future 
mortality and morbidity due to HIV are a useful aid in deciding on priorities for health research, 
capital investment and training.  
Aims and Objectives: 
 To detect HIV infection using  Fourth Generation Enzyme Linked Immunosorbent Assay 
and to compare the results of Test 1 (Fourth Generation ELISA) with Test 2 (Rapid Assay) 
Methodology: 
200 patients consisting of High Risk Group and Contacts of High Risk Group attending the STI 
Out Patient Department, Institute of Venereology, Madras Medical College/RGGGH, Chennai 
were enrolled for the study.Fourth Generation ELISA for HIV infection was conducted on these 
selected patients along with routinely done Rapid Assay for HIV infection.  
Results: 
The percentage of patients tested Positive by Fourth Generation ELISA out of the 200 study 
group was 37% and Negative was 63%. The detection rate of HIV Positivity by Rapid Assay in 
High Risk Group was 11% ad Negative was 89%.  
Conclusion: 
In this study, in most of the categories, the percentage of HIV Positivity detected by Fourth 
Generation ELISA was higher than that detected by Rapid Assay showing that Fourth 
Generation ELISA is a more sensitive test than Rapid Assay. A late diagnosis of HIV infection 
can result in increased transmission, morbidity, mortality and cost to health care services. Hence, 
early detection of HIV infection by Fourth Generation ELISA during the window period 
prevents transmission and above all improves the chances of early intervention. 
 
Key Words: HIV, Fourth Generation ELISA, Rapid Assay 
 
 
1INTRODUCTION
AIDS was postulated initially as an infective condition  way back in
1981(Gotlieb et al)(1) . The research for the identification and nomenclature
of the agent continued till 1986 (Coffin, et.al., 1986). The International
Committee on Taxonomy of viruses suggested the terminology "Human
Immuno Deficiency Virus” (HIV) to the agent identified and named such by
Montgainer and coworkers (1983) and HTLVIII isolated and recognised by
Dr. Robert Gallo and associates (1984) and named as such
(Gallo, et.al.,1984). So, it was in 1983-84 that the causative virus was
isolated from victims of AIDS and was christened HIV in 1986(2).
Within a span of four decades, it has established  to become a global
pandemic imposing a major threat to different walks of life. It has immense
effect on social as well as economic perspectives of   Nations. In 2006, there
was a probable estimate of 2.9 million deaths from AIDS throughout the
world.
Almost 95% cases hail from developing nations. An estimated 39.5
million people were believed to be living with HIV infection in December
2006(3). It accounted for nearly 2.5 million infected cases more than those
reported in 2004.
2REVIEW OF LITERATURE
Incidence
Worldwide there are forty million population living with Human
Immunodeficiency Virus (HIV)/ Acquired Immuno Deficiency Syndrome
(AIDS). Probable projections of future mortality and morbidity are a useful
aid in deciding on priorities for health research, capital investment and
training(4). HIV stands first among the leading causes for morbidity and
mortality.
In many parts of the world, new HIV cases are heavily concentrated
among the youth population (15 -24 years of age), which accounted for 40%
of it in the year 2006.
Number of people living with HIV all over the world in 2006:
Global prevalence of HIV infected  - 39.5 million
Adults Infected  with HIV - 37.2 million
Females Infected with HIV - 17.7 million
Children less than 15 years infected by HIV - 2.3 million
In Sub Saharan Africa, for every 10 adult men living with HIV, there
are approximately 14 adult females infected (59%) with HIV. Almost 25
3million people are living with HIV in Sub Saharan Africa, which accounts
for 63% of total global HIV infection. Also, 2.1 million people succumbed
to AIDS in Africa (ie 3/4th of global mortality). South Africa is the worst hit
along with Mozambique and Swaziland, whereas Zimbabwe is the only
Nation with declining HIV prevalence.
In Asia, South East zone remains the highest in HIV prevalence with
case loads excessive in India, Pakistan, Nepal, Cambodia, Thailand and
Vietnam due to MSM. In China, the incidence is on the ascending trend in
females. The ethnic and racial minorities are disproportionately affected in
United States of America.  Among the Eastern European & Central Asian
countries, HIV prevalence keeps escalating in Ukraine.
Hence, as per WHO and UNAIDS estimation in 2006, SubSaharan
Africa leads the list in HIV prevalence, followed by Asia, Northern America,
Western and Central Europe.
Indian Scenario
According to recent estimation based on National Family Health
Survey (NFHS), released by (NACO) National AIDS Control Organization,
the National HIV prevalence in India among the adult population is
approximately 0.36% which corresponds to an estimated 2 to 3.1 million
people living with HIV in our country. Out of these, 0.97 million (39.3%)
are females and 0.09 million (3.8%) belong to paediatric population.
4The high prevalence States are Tamilnadu, Karnataka, Maharashtra,
Andhra Pradesh, Manipur and Nagaland. The epidemic in India is highly
heterogenous due to the diverse modes of disease transmission in each state.
Most of the earlier cases had occurred through heterosexual sex; but at the
end of the 1980s, a quick spread of HIV was observed among injectable drug
users in Manipur, Nagaland and Mizoram(5). Even within the same State, the
prevalence varies among districts.  Hence, NACO has categorized districts.
1 >1% ANC/PPTCT prevalence at any time in a district in
the previous 3 years
A
2 <1% ANC/PPTCT prevalence in all sites  in the
preceding 3 years associated  with > 5% prevalence
amongst HRGs
B
3 <1% ANC/PPTCT prevalence in the preceding 3 years in
all sites  furthermore associated  with < 5% prevalence in
all STD clinic attendees /HRG with recognized hot spots
(migrant, tourists, truckers, large aggregation of factory
workers, etc)
C
4 <1 % ANC prevalence in last 3 years in all areas with <
5% prevalence among STD clinic attendees / HRG / no
or poor HIV data with no established hot spots
D
HIV prevalence was projected to be  >1% among antenatal mothers in
95 districts, including 9 districts belonging to  the low-prevalence States.
5HIV prevalence has started to decline in Tamilnadu and other
Southern States which have reportedly a high HIV burden. There has been
feminization of this HIV epidemic with an estimated 38.4% of infected
adults being women(6) .
There are about 4000 integrated counselling and testing centers
(ICTCs) in India. About 80,000 HIV infected people are accessing free
antiretroviral treatment (ART) in 127 centers. PPTCT program has been
scaled up in the county with Nevirapine as the drug of choice.
6History of HIV in India
India's initial few cases of HIV were detected among sex workers in
Chennai, Tamil Nadu.  Intavenous drug users had contributed to a worse
scenario in Manipur, Mizoram and Nagaland (7).  In  1987,  a  National  AIDS
Control Programme was launched to coordinate Nation level control
activities. Its activities included surveillance, health education and blood
screening (8). In 1992, Indian Government formulated  NACO (National
AIDS Control Organisation), to oversee the formation and execution of
policies, prevention work and control programs related to HIV and AIDS. In
2001, the Government adopted the National AIDS Prevention and Control
Policy(9). NACP III was launched officially on 6 th July 2007 (10) with a motto
of halting or reversing the HIV epidemic in India  by 2012. Whereas NACP
IV   launched in 2012 aimed at zero HIV incidence, zero stigmata, zero
discrimination against HIV infected and zero AIDS related death .  NACP
has declared a 56% decline in  HIV incidence in the last decade.
India housed 5.7 million HIV/AIDS patients (people aged between 15
and 49 years) way back in 2005, including the pediatric AIDS cases. The
HIV/AIDS epidemic is affecting females and young girls more, especially
where heterosexual sex is the main mode of transmission(11). Out of the
estimated adult population living with HIV, 38.4% were women(12).
7The overall HIV prevalence among different sector of population  in
2007 continues to picturise the concentrated epidemic in India, with a very
high prevalence among High Risk Groups - IDU (7.2%), MSM (7.4%), FSW
(5.1%) & STD (3.6%) and low prevalence among Antenatal clinic attendees
(0.48%).
8HIV in Tamil Nadu
As per NACO study in 2004 -2006, amongst 32 districts, 22  fall
under Category A. They include Coimbatore, Erode, Namakkal,
Thoothukudi, Cuddalore, Kanyakumari, Karur, Madurai, Dharmapuri,
Krishnagiri, Pudukottai, Perambalur, Ramanathapuram, Theni, Salem,
Sivagangai, Nilgris, Vellore, Thiruvallur, Tiruchirapalli, Thiruvannamalai
and Virudhunagar.  Whereas, Chennai, Kanchipuram, Tirunelveli,
Villupuram and Thanjavur districts were tabulated under Category B.
Thiruvarur, Dindigul and Nagapattinam  were assigned into Category C.
9The HIV prevalence at antenatal clinics in Tamilnadu was 0.88% in
2002 and 0.5% in 2005, though many districts still have rates above 1%.
Prevalence among Intravenous drug users was 18% in 2005. Tamil Nadu had
reported 52,036 AIDS cases to NACO by July 2005, which is by far the
highest number reported by any State(12).
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Also, there are cases of HIV 2 reported in Tamilnadu especially in
southern districts especially Tirunelveli(13) .
Spread of HIV
The HIV pandemic has undergone four critical stages of evolution
1. Emergence  - from remote rural areas
2. Dissemination to various parts of world  due to population migration
and world wide travel
3. Escalation  - when transmission was increased by high risk groups
4. Stabilisation – In Australia, North America and Western Europe
(LANCET)
The approximate risk of acquiring HIV infection after different types
of exposure is less compared to risk of infection with HBV or HCV. Blood
transfusion has the utmost chance of transmitting HIV of nearly 90 – 95%.
Mode of Exposure
Chance of
Transmission
(in %)
Blood and Blood product transfusion 90-95
Perinatal and Intranatal transmission 20-40
Mother to Child transmission 13 -48
Sexual intercourse 0.1 – 10
Vaginal intercourse 0.05 – 0.1
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Anal intercourse 0.065 – 0.5
Oral  intercourse 0.005 – 0.01
Intravenous drug use 0.67
Needle stick exposure 0.3
Mucosal splash to eye/ nose/mouth 0.09
Mode of
exposure
Cause of infection
world wide in
percentage
Cause of HIV
infection in India-
percentage
Blood transfusion 5 2.5
Perinatal 10
Sexual 75 86
Vaginal 60 85
Anal 15 0.548
Oral Case reports only
Intravenous drug
use
10 7.3
Needle stick
injury
0.1 0
Others 10.92
The above information concerning Indian statistics have been
published in NACO website.
In contrary to common  belief that saliva can transmit HIV, it is not
so. Saliva contains some nonspecific inhibitory substances like fibronectins
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and glycoproteins  and salivary leukocyte protease inhibitor (SLPI) which
could avert cell to cell transfer of virus.  Thus, saliva is not a likely mode of
transmission. Sweat, milk, tears, amniotic fluid, synovial fluid, broncho-
alveolar lavage fluid, faeces and urine have been reported to yield zero to a
few HIV particles.  Hence, these vehicles are also not proposed to be
important in virus transmission.
Breast milk at the time of primary acute HIV infection in a lactating
mother has a high concentration of virus and may transmit the infection to
the baby.  Cerebrospinal fluid (CSF), on the other hand, also has a high viral
concentration particularly in individuals with neurological involvement, but,
CSF is not a natural source of virus transmission.
India's epidemic appears to follow the Type 4 pattern , initially
postulated in Thailand.
High Risk Groups       Bridge population    General population
The shift in groups occurs when the prevalence in preceding group
reaches 5%. The time lag between such a shift is around 2 -3 years.
High Risk Groups
They are the core groups including
? Commercial sex workers
? Partners of HIV/ VDRL reactive patients
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? Transgenders / Homosexuals
? Victims of sexual abuse
? IV drug abusers
? H/o multiple blood transfusions
? Occupational exposure to blood products with exposure code 3 and
risk code 2.
Commercial sex workers spread the infection to the bridge population
with  the transmission rate of 0.033 to 0.1%. The co existence of other STIs
favour a quicker transmission of infection.
In transgenders and men having sex with men, unprotected anal
intercourse puts the individual at a risk rate of 0.5 to 3% which is much
higher than that of a male to female or female to male vaginal sex either
way. Though open acceptance for Gay relationship is controversial,
considerable number of men continue to be MSMs and keep it secretive. So
limited is their knowledge of prevention and awareness of   STIs and HIV.
Alcoholics may also be included in this category due to higher unsafe sex
practices prevalent among them(14) and higher chance of condom slippage
and other risk factors.
In Vellore, a study indicates that the prevalence of HIV 1 antibodies
among CSWs increased from 1.8% in 1986 to 28.6% in 1990.  The
prevalence of HIV infection among STD patients has increased from 0.19%
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in 1986 to 3.9% in 1992. Also, the HIV incidence was 9.7 per 100 person
years in men with recent exposure to CSWs without proper protection
compared to 5.6 per 100 person years in men without such an exposure, as
per a study conducted in Pune (15).
Co Factors involved in HIV transmission
The huge list of co factors can be enumerated which facilitate the
transmission of HIV infection. They are
? Co existence of other STIs escalates the  risk by 300 -400%
? Ignorance in the part of source as well as the victim
? Condom slippage/ tear
? Late marriage in men / women  increasing incidence of pre marital sex
? Low socio economic status, financial burdens and  human trafficking
? Lack of proper antenatal visits
? Alcoholism
? Recapping of needles
? Improper handling/ segregation of hospital wastes
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Human Immunodeficiency Virus
HIV belongs to retroviridae family and lentivirinae subfamily. They
are of 2 types namely HIV 1 and HIV 2. HIV 1 resembles  SIV cpz isolated
from chimpanzee subspecies Pan troglodytes troglodytes and is distributed
world  wide.  HIV  2   resembles  SIVsm   isolated  from  Sooty  Mangabey
monkeys and is found to be virulent. HIV 2 was first isolated from West
Africans.
The strains of HIV 1 are divided into two groups as Major and Outlier
indicated as M and O respectively. Furthermore, group N has been
described in Cameroon. Group P has been isolated from Gorilla.  The M
group has nine subtypes called as clades A to K excluding E and I along
with increasing major and minor circulating recombinant forms (CRFs).
India - Subtype C mainly, B and recombinant
HIV (C and A).
Thailand - Sub type B and E.
United States and Europe - Sub type B.
CRFs are formed due to dual subtypes infection which recombine and
create a virion with an added advantage. An example is AE form despite the
fact that a pure parenteral E infection is yet to be detected. Furthermore,
subtypes A and F are further classified into A1, A2, F1 and F2. The globally
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most prevalent seven strains are HIV 1 subtype A, B, C, D, G, CRF01_AE
and CRF02_AG. Of all these, subtype C is in the lead.
HIV 2 has further been subclassified into groups from A to G. In
general, the group with utmost significance is HIV 1 Group M  as this has
contributed to the global pandemic. Whereas, HIV1 Group O and HIV 2
though found in many countries off late, contributes to localized epidemics.
It comprises of a central electron dense nucleoprotein core with two
positive single stranded RNA copies, nucleocapsid  and capsid proteins, viral
enzymes integrase, protease and reverse transcriptase which are surrounded
by an envelope. The capsid protein constitutes the icosohedral viral core
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which is hydrophobic and is the major internal structural feature of the virion
comprising the shell of viral core. On its outer surface lies a lipid bilayer
constituting surface (gp120) and transmembrane (gp41) envelope
glycoprotein(16). The matrix protein lines the inner surface of the lipid
bilayer.
The proviral DNA form of HIV 1 genome contains 8.5 to 9 kb of
protein coding information flanked on either sides by long terminal repeats.
The coding portion codes for 9 different genes
? Structural genes –  gag, pol, env
? Regulatory genes – tat, rev, nef
? Accessory genes – vpu, vif, vpr
Gene Type Function
Env Structural gene Codes gp 160 (120 &41)
Gag Structural gene Codes internal proteins forming core of
virion (p24,7,9)
Pol Structural gene Encodes  ( p7, 9, RNA, reverse
transcriptase, integrase, protease)
Tat Positive
regulatory gene
Tansactivator of transcription
Nef +/_  regulatory
gene
Negative regulation factor
Rev +/_  regulatory Regulator of expression
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gene
Vpr Weak positive Transcriptional activation ; Moderate
activator of LATS
Vpu ?negative Not found in HIV 2; If defective, virus
replicates quickly
Vif Infectivity Virion infectivity factor
The  main variation between HIV 1 and 2  is that HIV2 lacks vpu gene
and  has  vpx  instead.  This  vpx  gene  is  absent  in  HIV  1.  There  are  a  lot  of
sequence diversities in HIV isolates, mainly clustered in the hypervariable
regions.
Pathogenesis
The steps occurring in infection involve an interaction of HIV not
only with the CD4 molecule on cells but also with other cellular receptors
and antigen presenting cells(17) .
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HIV can infect different types of cells such as CD4+ helper T-cells
and macrophages that express the CD4 molecule on their surface.
Macrophage (M-tropic) strains of HIV-1 or the non-syncitia-inducing
strains (NSI) utilise the beta-chemokine receptor CCR5 for entering the cell
and are thus capable of replicating in macrophages and CD4+ T-cells(18).
These strains are now labelled as R5 viruses. This CCR5 co receptor is
utilised by almost all primary HIV-1 isolates regardless of viral genetic
subtype.
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T-tropic isolates or the syncitia-inducing (SI) strains replicate in
primary CD4+ T-cells as well as in macrophages and utilise the alpha-
chemokine receptor, CXCR4, for gaining entry into the cell(19,20). These
strains are now labelled as X4 viruses. The alpha-chemokine, SDF-1, which
is a ligand for CXCR4, suppresses the replication of T-tropic HIV-1 isolates.
Viruses that use only the CCR5 receptor are termed R5, those that
only use CXCR4 are termed X4, and those that use both, X4R5. Apart from
CD4 cells, the dendritic cells expressing C type Lectin named as DC sign.
HIV's replication cycle gets initiated with the high affinity binding of
V1 region adjacent to N terminal of gp120 to CD4. This induces some
conformational variations in gp120 which facilitates the binding to
abovesaid coreceptors namely CCR5 and CXCR4. After the interaction of
virus and the host cell receptor, fusion of viral as well as the cell membranes
occur as gp41 penetrates the plasma membrane of the target cell and viral
core ventures into target cell cytoplasm forming a pre integration complex
consisting of viral nuclear material, its enzymes and capsid coat. By the
action of reverse transcriptase, double stranded DNA is synthesised by
having ssRNA  as a template forming the proviral DNA. This stage is
inhibited by APOBEC group of cellular proteins. These are counteracted by
the viral protein vif factor by means of proteosomal degradation. It is
followed by integration of viral DNA with host DNA within introns of active
genes and their hot spots by the action of integrase enzyme.
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RNA polymerase II aids in viral replication using integrated  provirus
as a template which is further converted  into spliced and non spliced  viral
mRNA  transcripts encoding regulatory and structural viral protein. Finally,
they get assembled along with genomic length RNA and budding of virion
from host cell surface from specialised regions in the lipid bilayer called as
lipid rafts occurs  releasing free infective virions.  Proteases catalyse the  gag
pol precursor cleavage to finally  release the mature virion.
Stages of HIV Infection
Following infection with HIV, there is a time period called as
transmission bottle neck. It further leads to an initial eclipse phase where the
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infection is localised to the tissue at that particular exposure site when there
is no serological changes in blood.  This phase exists for approximately 10
days. There is further spread to the regional lymphoid tissue and then into
the systemic circulation with a viral replication time of 20 hours. A week
after the stage of viremia, p24 Ag gets detected in blood. This p24 Ag
detection occurs once HIV RNA copies exceeds 10000 copies/ml of
blood(21).
During this period of time, the architecture of lymphoid tissues is
profoundly altered, with dramatic depletion in CD4+ lymphocyte count,
widespread immune stimulation and establishment of central nervous system
infection. Finally, as cellular and humoral immune responses emerge, viral
loads decline and stay at much lower levels associated with the initial set
point(21,22). The end of the phase of acute infection leads, in most cases, to the
initiation of the long clinical latency of HIV infection.
The onset of symptoms of Acute HIV infection starts roughly a
fortnight after acquisition of infection due to cytokine storm.
Approximately, 5 -7 days following p24 Ag detection, anti HIV antibody
reach levels detectable in blood(21).
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A proper understanding of the phases in HIV infection is important in
realizing the significance of detecting early cases of infection(23).The rate of
HIV transmissibility per coital act was highest during the pre said early-
stage of infection. This has implications and practical significance for HIV
prevention and for projecting the effects of antiretroviral treatment on HIV
transmission .
In a prospective study of patients attending STD clinics in India,
screening for p24 antigen in HIV antibody negative people was found to be a
reliable and effective research method for accessing recent risk behavior and
clinching at the clinical signs of acute primary HIV infection (24).
From the initiation of infection, the level of HIV 1 in serum and
semen seems to be directly proportional. But in the course of disease, the
risk of transmission per coital act does not remain the same. It keeps
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changing depending on altering viral load. These acute dynamics alone are
sufficient to predict the increase in probability of heterosexual transmission
by 8–10-fold between peak (day 20 after infection) and virologic set points
(day 54 and later after infection) (25). Depending on the frequency of sexual
act, men with an average semen HIV-1 loads and without sexually
transmitted diseases (STDs) would be predicted to infect 7%–24% of
susceptible female sex partners during the first 2 months of infection. The
risk of transmission is further increased with other co existing sexually
transmitted infections(26).
A research conducted in Uganda projects that the average HIV
transmission was 0.0082/ coital act within 2.5 months following
seroconversion; 0.0015 /coital act within 6 to15 months following
seroconversion; 0.007/coital act among HIV prevalent index partners and
0.0028/coital act few months before the death of the index partner. Early and
late stages of  infection, genital ulcer disease, higher viral load, and younger
age of the index partner were significantly associated with higher rates of
spread.
The rate of HIV transmission per coital act was thus assessed to be the
highest during early stage of infection(27) .
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HIV and other Sexually Transmitted Infections
The other co existing sexually transmitted infections act as
augmentators or cofactors for transmission of HIV. This is termed
epidemiological synergism(28). Apart from the increased HIV shedding in
most of the secretions, another common factor is sexual promiscuity.
Increased HIV spread is because of already broken mucosal barrier
and  a favourable environment with due to prior recruitment of HIV
susceptible inflammatory cells like CD4+ T cells. On the other hand, in HIV
infected, the cell mediated immunity is already compromised  rendering the
person more vulnerable to other STIs.
Odds ratio of the risk of acquiring HIV infection in association with
other STIs are as follows:
Genital ulcer disease  : 3 -18
Chlamydial Urethritis  : 3 -6
Gonococcal Urethritis  : 3.5 to 9
Trichomoniasis :  3
Genital Herpes :  2
In HIV infected patients, other STIs presume an atypical presentation,
prolonged course and a wide dissemination occurs with systemic
involvement. Reactivation of a previous forgotten sexually transmitted
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infection also occurs in HIV infected. Drug resistant strains both bacterial
and viral are also another issue of concern in HIV infected people
developing other STIs.
Destruction of HIV(29)
Sterilization
-  Autoclaving at 1210C, for 20 minutes under15 lbs pressure.
-  Dry heat 1700C for 60 minutes.
-  Boiling for a time period of 20-30 minutes.
Chemical disinfection
-  Sodium hypochlorite: 5gm/litre. (0.5 to 1% ordinarily, 5-10% for high
   organic matter content e.g. discarding tissues etc.)
-  Calcium hypochlorite: 1.4 gm/litre
-  Chloramine : 20gm/litre (Available chlorine 0.1%)
-  Formalin : 3-4%
-  Ethanol : 70%
-  Povidone iodine (PVI)
-  Glutaraldehyde : 2% for 30 minutes
Diagnosis of HIV
The screening tests employed in detection of HIV are ELISA and
Rapid assays.
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Enzyme Linked ImmunoSorbent assay is a widely employed method
for detecting HIV.  Many samples are tested at the same time and results
were obtained within four hours.  In most of the people, detection of
antibody in serum is possible within 6-12 weeks after infection using the
previous generation of assays. This window period is decreased to 3-4 weeks
when using the newer Third Generation ELISA. The additional advantage of
detecting p24 Ag helps the latest Fourth-Generation ELISA to pick up
infections 5 to 7 days prior. The total window period can be shrunken to two
weeks using p24-antigen assay(30).
Enzyme Linked ImmunoSorbent Assay
The fundamental principle of ELISA is to utilise an enzyme to detect
the antigen antibody complex formation. The enzyme transforms a
colourless substrate to a coloured end product, indicating antigen and
antibody binding. There are two main types namely Non competitive and
Competitive ELISA. The Non competitive ELISA includes Indirect, Direct
and Sandwich ELISA.
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False  Negative ELISA is predicted in the following conditions:
? Window period
? Terminal stage  due to immune depletion
? Technical error
? Different subtype/ clades
False Positive ELISA occurs in
? Auto immunity
? Multiple transfusions
? Haemodialysis
? Multiple pregnancy
? Antibody to Class II HLA
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? Acute Ebstein Barr virus infection
? Acute Cytomegalo virus infection
? Increased Immunoglobulin
? Vaccination for  Hepatitis B/ Influenza
? Chronic alcoholic
There are four generations of ELISA(31)
First Generation :  Crude antigen extracted from viral lysates  was utilised.
It could detect only HIV 1 and specifically IgG. It has increased sensitivity
with lesser specificity.
Second Generation: Antigens are more refined and is a recombinant
antigen extracted either from bacteria or fungi.
Third Generation:  The antigen used is a synthetic polypeptide comprising
of about 15 to 40 aminoacids. Detects both IgM and IgG of HIV 1 and 2. In
this test, the window period is around 3 to 4 weeks following acquiring the
infection.
Fourth Generation :  It is the latest combo assay. It has an additional
advantage of detecting p24 in addition to antibody detection due to coating
of microtitre plate with both antigen and antibody.
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Rapid assay has the immense advantage of quicker total reaction time
of less than thirty minutes. It offers the opportunity to perform multiple
assays at the same time with minimal cost. It also provides the additional
advantage of not requiring any sophisticated or expensive modern equipment
to perform the test or interpret the results .The other advantages are that test
result read by naked eye and so do not need  microscopic settings. The
following methodologies are included in rapid tests
? Immunoblot technique
? Immunochromatography
? Red cell haemagglutination
? Membrane immuno concentration
? Particle agglutination
? Magnetic bead
Of all the above said methods, the most commonly employed one is
dot blot assay(32,33) .
It utilizes nanogram quantities of HIV lysate, along with microliter
amount of serum or culture supernatants for the detection of antibody. The
microscopic sized particles are coated with a synthetic peptide which are
then immobilized on a nitrocellulose membrane. To the patients serum
(which supposedly contains anti HIV antibodies), conjugate, developer and
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stop solutions are added in sequence after appropriate incubation time and
washing. Colour develops in proportion to antibody level in serum.
The other supplementary tests are
Western Blot
This is a highly specific test with equal sensitivity as rapid assay and
ELISA. The major crippling factor is the high cost incurred. The specific
viral proteins derived from the whole viral lysate is run through gel
electrophoresis. The various proteins are separated based on molecular
weight and are blotted on nitrocellulose strip. The antibodies in blood get
immobilized and attached to the proteins and a colorimetric reaction occurs
on addition of enzyme, conjugate and substrate. The presence of coloured
bands, confirms the sample positive for HIV.
Immunofluorescence test
Fluoroscein labeled anti human antibody is employed to detect the
presence of anti HIV antibodies. A positive result is confirmed by
development of an apple green fluorescence. Technical expertise is a major
curbing factor in carrying out this otherwise inexpensive test.
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Line Immuno assay
It bears lot of resemblance with Western blot except for the fact that a
recombinant or synthetic peptide is used as an antigen.
Confirmatory tests
They include
Virus isolation
HIV virus is cultured by co cultivating HIV negative person´s
peripheral blood mononuclear cell. It needs an average time of one week
from acquisition of infection. There is also a microculture method described.
Both methods picked up more than 75% of the positive cultures within a
week and 100% of the positive cultures within a fortnight(34) .   The  main
disadvantage is that a negative test does not rule out HIV, one week mean
period required for detection and expertise needed.
p24 antigen – HIV specific core antigen detection:
Identifying cases in the acute stage of infection, particularly before
detection of antibodies is very crucial in epidemiological, clinical and social
point of view(35) .Understanding the intensity of transmission in the early
infective period, the usefulness of psychological counselling and  guidance
regarding sexual abstinence or barrier methods need not be overemphasised.
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Another noteworthy issue is mother to child transmission, which can also be
prevented by intake of antiretroviral drugs after early detection of infection
in a pregnant mother.
In 1985, in the United States of America, there was a study stating
acquisition of HIV in recipients of blood transfusion whose donors were
screened negative for HIV antibody at that point of time. Thus, it was then
stressed that new assays which pick up HIV infection earlier should be
evaluated for their effectiveness in screening donated blood (36).
By definition, antibody tests cannot generally identify cases of early
acute HIV infection. Current rapid antibody tests detects HIV approximately
during the fifth week of infection, after the occurrence of peak viremia (37). A
variety of tests exist that can pick up acute HIV infection before the
currently employed standard EIAs and rapid antibody tests, including HIV
p24 antigen immunoassays, Fourth-Generation immunoassays (which
combine antibody and p24 antigen detection), and HIV NAATs.
Recognizing the limited ability of antibody tests to detect acute HIV
infection, a number of large public testing systems in other countries have
successfully implemented either p24 antigen tests alone, combined antibody
and p24 antigen (Fourth-Generation immunoassay) [29] tests, or antibody
and NAAT screening algorithms, to detect both acute and non acute HIV
infections.
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p24 antigen assay is useful not only in these early acute HIV
infections, but also in newborn of reactive mothers where the maternal anti
HIV antibodies misinterpret the other routine tests. Also, in HIV
encephalopathy and dementia, a CSF p24 antigen can be searched for. p24
detection can be done by three methods namely
? Indirect ELISA
? Ultrasensitive p24 detection test – dissociation of immune complex
before subjecting to ELISA
? RT – PCR
Polymerase Chain Reaction
It is the most sensitive test with the immense capacity to amplify even
a single strand of proviral DNA. It aids in diagnosing cases earlier than viral
culture.
The methods employed are
? RT PCR
? NASBA (Nucleic Acid Sequence Based Amplification)
? Branched DNA assay
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National AIDS Control Organisation (NACO) Protocol:
The testing algorithms are based on prevalence of HIV in that area and
the purpose of testing.
Testing algorithm - I
Purpose : Blood Transfusion
Done in : Zonal blood testing centre / Blood banks
Requirement : only one highly sensitive and reasonably specific test
(ELISA) / anonymity maintained.
If positive, the blood is discarded.
Testing algorithm - II
 Purpose : Serosurveillance
Tests : Two EIA are done, the first one very sensitive and the
second test very specific.
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Anonymity is maintained throughout. If serum is positive by first test,
then a second test is done on the same sample. Only if positive by second
test also, sample is considered positive and if not considered antibody
negative.
Algorithm - III
Purpose  :  Diagnostic purpose
Number of tests done are three EIAs, with each one based on different
antigen or principle.
In asymptomatic people, a positive first test is followed by second and
third tests.
If positive by all three tests, sample is labelled positive
If negative by first or second test, again the sample is labelled
negative
If positive by first and second test, but negative by third test, the
sample is considered borderline or equivocal. Such samples are re tested
with second and third test and also by Western blot for which sample is
taken  2-3 weeks later.
In symptomatic, algorithm II holds good.
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In a population with > 10% HIV prevalence, algorithm I is used in
serosurveillance and algorithm II is used in asymptomatics.
Targeted Interventions by NACO
NACO states that the most effective means of controlling the spread
of HIV in India is through the implementation of Targeted Interventions
(TIs) among individuals who are more susceptible to HIV/AIDS, such as
female sex workers (FSWs), men who have sex with men (MSM),
transgenders (TGs) and injectable drug users(IDU). In addition, the bridge
populations of truckers and migrants also require a more focussed
intervention. Both NACO and the States gives a high priority upon
full coverage of the States’ FSWs, MSMs/TGs, IDUs and migrants/truckers
with TIs.
According to the framework of NACP III, prevention strategies will
have a three pronged approach:
1. Core High Risk Groups (HRGs): There are three core HRGs — female
sex workers (FSWs), high risk men who have sex with men and transgenders
(MSM and TGs), and injecting drug users (IDUs).
2. Bridge populations:  NACO gives prime focus on clients of sex workers:
Clients benefit with a combination of services including condom promotion,
referrals to clinical services for STI management and behavioural change
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communication (BCC). Specific strategies have been outlined to approach
two major populations within the bridge population: truckers and high risk
migrants.
3. Other Vulnerable Populations: Risk groups in rural areas, HIV affected
children, youth 15 - 19 years old and women receive a package of services
delivered through a more extensive mechanism – that of link workers.
Studies state that in general a fulltime FSWs have at least one client
per day, or at least 30 clients per month, and nearly 400 per annum. Some
FSWs have 100 or more clients in a month. The higher risk of FSWs is
reflected in a substantially higher prevalence of HIV among them than in the
general population.
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In India, Sentinel Surveillance data has shown that HIV prevalence
among FSWs is generally 10 - 20% or more, which is more than ten times
higher than among pregnant women attending antenatal clinics.
Within one year, 1,000 FSWs will have sexual contact with roughly
300,000 to 1,000,000 clients. In the contrary, 1,000 “high risk” men who
have 6 - 12 sexual partners in a year will have a total of 6,000 -12,000
sexual partners per annum. Since the HIV prevalence is much higher among
FSWs, a higher proportion of their sexual partnerships could result in HIV
transmission more so in the stage of early acute HIV infection. The number
of HIV positive sexual contacts for 1,000 FSWs is much greater than for the
same number of high risk men. This demonstrates the strategic importance
of focusing prevention programmes on FSWs.
MSMs and Transgenders
There are MSM subpopulations which do have high rates of change in
partner as well as high number of concurrent sexual partners, and those who
often engage in anal sex with multiple partners are at high risk and more
vulnerable, since HIV is more transmissible through anal sex than by other
sexual practices(38). Members of the transgender population who have many
male partners are also at high risk, since many of them engage in anal sex.
Because  many  men  who  have  sex  with  both  high  risk  MSM  as  well  as
transgendered individuals also have other partners, both male and female,
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targeted interventions for these HRGs are strategically critical to controlling
the HIV epidemic.
Injecting Drug Users (IDUs)
IDUs are a third HRG for which targeted interventions are of critical
importance. HIV is highly transmissible through the sharing of needles and
other injection equipment, so it can spread very rapidly within the wide
networks of IDUs who share injections and other equipments with each
other. Once HIV prevalence is high in the IDU sector, it can extend quickly
into their sexual networks too since sexual promiscuity is commonly present
in the IDU sector. Some IDUs are also full fledged sex workers, which can
rapidly link HIV spread in the IDU networks to transmission in the larger
high risk sexual networks. The HIV prevalence among IDUs in Kolkatta was
reported to be 1%(39) .
It is important to understand that, like sexual transmission of HIV,
HIV is essentially preventable among IDUs and their sex partners too.
Interventions that are implemented early (HIV prevalence <5% among
IDUs) are most efficient in decreasing the spread of the HIV epidemic
among IDUs. HIV interventions targeting the majority of IDUs can stabilise
and even reverse the escalating HIV epidemic among them.
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The NACO strategies works on typology of female sex workers in to
six categories and MSMs and IVU. They focus on reaching these HRGs in
the field, forming a community based organizations, free condom supply and
ensuring its availability, training and developing peer educators and
propagating peer education .
Thus this study takes into account the magnitude of infection among
the HRGs and the significance of earlier detection of HIV infection using
p24 as well as the anti HIV antibodies.
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AIM AND OBJECTIVES
1. To detect HIV infection using  Fourth Generation Enzyme Linked
Immunosorbent Assay
2. To compare the results of Test 1 (Fourth Generation ELISA) with
Test 2 (Rapid Assay)
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MATERIALS AND METHODS
Study Setting : Institute of Venereology
                            Madras Medical College /
 Rajiv Gandhi Government General Hospital,
 Chennai – 600003.
Study Period : One year (September 2013 – August 2014)
Study Observation : Prospective Observational Study
Sample Size: 200 patients consisting of High Risk Group and Contacts of
High Risk Group attending the STI Out Patient Department, Institute of
Venereology, Madras Medical College/RGGGH, Chennai were enrolled for
the study.
The Ethics Committee approval was obtained and informed consent
was taken from those patients who were enrolled in the study.
Study Population: High Risk Group and Contacts of High Risk Group
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Inclusion Criteria
Patients attending STI Out Patient Department  with high risk behaviours:
1.  Commercial Sex Workers
(including Female and Transgender Sex Workers)
2.  Men with recent or recurrent exposure to Commercial Sex Workers
3.  Females whose husbands were promiscuous and had multiple
exposure to  Commercial Sex Workers
4.  Transgenders
7.  Men with Homosexual Behaviour
5.  Partners of HIV seropositive patients
6.  Partners of VDRL reactive patients
8.  Victims of Sexual Abuse
9.  Intravenous Drug Abusers
10. H/o Multiple Blood Transfusions
11.  Occupational Exposure to Blood Products with Exposure Code 3 and
Risk Code 2
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Exclusion Criteria
1. Known HIV positive patients
2.  Patients who refuse to participate in the study
3.  Patients less than 10 years
After fulfillment of the above inclusion criteria, patients were
shortlisted and enrolled in the study.
Detailed clinical history  which included age, gender, sexual
orientation, occupational history, marital history, sexual history/ last
contact, premarital and extramarital contact, HIV seropositivity in contacts,
history related to present and past H/o sexually transmitted infections in
patients as well as partners, followed by thorough clinical evaluation was
done. Also, approach by the patient to STD department whether by self
approach or referral from other medical fraternities or whether brought by
NGO were recorded. Furthermore, willingness of the patient to give contact
information including telephone number and contact address was noted
which indirectly shows the approachability and accessibility to such patients.
History regarding the clinical complaints for which they approached
STD department and other co morbid conditions like smoking, alcohol,
Tuberculosis were documented.  Furthermore, history regarding surgical
intervention and blood transfusions were noted. History regarding intake of
medications, previous treatments in STD clinic or any other health problems
were sought.
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Clinical Examination
In male patients, thorough genital examination was done with a
speculative search for urethral discharge, balanoposthitis, phimosis,
paraphimosis, genital ulcers or erosions, genital wart, genital molluscum
contagiosum, genital scabies and genital scars.
In female patients, a routine gynaecological examination was done
with Cusco`s self retaining bivalve speculum. Conditions like vulvovaginal
candidiasis, genital herpes, genital wart, abnormal cervical discharge,
abnormal vaginal discharge, genital ulcers or erosions were recorded if
present. Urethral and cervical discharges were subjected to Gram staining,
vaginal discharge was subjected to gram staining, KOH mount and saline
mount and examined under microscope.
In Homosexuals with ororeceptive practices, throat swab for
gonococcal culture was taken. Rectal swabs were taken for anoreceptive
homosexuals and gonococcal culture was done. From genital ulcers, Tzanck
smear, Gram staining and dark field microscopy was done to zero in on the
cause.
Genital ulcers, if present were scraped from base to rule out herpetic
lesions and serous discharge was subjected to dark ground examination.
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A complete general examination to rule out any immunocompromised
state or any coexistent diseases was done.
Investigations for other sexually transmitted infections like urine
analysis for sugar, culture sensitivity, VDRL and TPHA for Syphilis,
gonococcal culture were carried out.
Based on the above factors, Risk was assessed and High Risk patients
recruited for the study.
After counselling and after recording their consent for the test, Fourth
Generation ELISA for HIV infection was conducted on these selected
patients along with routinely done Rapid Assay for HIV infection.
5 ml blood was withdrawn aseptically from the patient. The serum was
separated and subjected to Fourth Generation ELISA as well as Rapid Assay
for detection of HIV infection.
Study Principle
Test 1: It is Generation Four Solid Phase Enzyme Linked ImmunoSorbent
Assay based on the principle of Double antigen/antibody sandwich
technique for the detection of the IgM and IgG antibodies against HIV 1
and/or HIV 2 and p24 antigen in human serum or plasma.
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Test 2: Dot ImmunoAssay employs the same principle as Enzyme Immuno
Assay whereby the immobilized antigen antibody complex is visualized by
means of colour producing (chromogenic) reaction. The coloured end point
is developed by a Colloidal Gold Protein - A Signal Reagent.
Fourth Generation ELISA
The  Fourth  Generation  ELISA  is  a  Solid  Phase  Enzyme  Linked
Immunosorbent Assay. It utilizes the Double antigen antibody sandwich
technique. It detects IgM and IgG Ab against HIV 1 & 2 and p24 Ag in
human serum/plasma.
The kit used in this study employs monoclonal antibodies to p24 and
highly purified antigens (recombinant) like gp41 (envelope glycoprotein ) of
HIV 1 and gp 36 (envelope glycoprotein)  of HIV 2.
Mechanism
The microwells in the kit are coated with p24 antibodies, gp41 and
gp36 antibodies of HIV 1 and 2 respectively. Samples along with both
positive and negative controls were added into the wells. Antigen antibody
complex forms. Then, the wells are washed to remove the unbound
components. To the bound immune complexes adherent to the wells,
biotinylated p24 antibodies were added which was followed by antigen HRP
conjugate. Washing of wells was repeated. The reactions were stopped at a
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specific time and absorbance was read at 450nm using an ELISA reader. Cut
off value was then calculated and the results were compared. Samples with
absorbance higher or equal to cut off value was considered positive or
reactive.
Fourth Generation ELISA Kit
The kit consists of 96 microwells coated with monoclonal p24
antibodies  and recombinant antigen of HIV 1 and 2.
Positive Control : Human serum reactive for HIV 1 which is stabilized and
inactivated along with preservatives.
Negative Control : Stabilised, preserved, inactivated non reactive Human
serum (non reactive to HIV 1,2, HBsAg and HCV).
Conjugate  : Antigen HRP conjugate to be diluted with the given
diluent. Antibody reagent : Biotinylated anti p24
Antibody (monoclonal).
Substrate  : Tetramethyl benzidine and hydrogen peroxide.
Stop solution  : Sulphuric acid ( diluted ).
Procedure
Samples taken were tested fresh or were short term refrigerated.
Unheated samples were used. Sample, kit, diluents, conjugates and all
reagents were brought to room temperature. 50 µl of sample diluent was
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added in all wells. Further 100 µL of control or specimen were added in
separate wells. This was incubated at 37degree centrigrade for thirty
minutes. Each well was washed with wash buffer 350 µL giving 30 seconds
soak time for six washes each. It was blot dried. After 100 µL of antibody
reagent was added, the kit was again incubated at 37 degree centigrade for
fifteen minutes. Blot dry the kit. 100 µl of diluted conjugate was added in
each well and incubated for further fifteen minutes at 37 degree centigrade.
The washing procedure as mentioned earlier was done six times. 100 µL of
substrate was added in all wells, incubated at room temperature for thirty
minutes. 100 µL of stop solution was added into each well in the same order
as substrate was added. Finally, absorbance was read within half an hour of
stopping the reaction at 450nm with reference range kept as 600 - 700nm.
Inference
Absorbance value of negative controls : < 0.1
Absorbance value of positive control : >1
If test run fails to meet the above criteria, it is invalid.
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Procedure Flow Chart
50 µL of sample diluent in each well
100 µL control / specimen addition
Incubate at 370C for 30 minutes
100 µL antibody reagent added and incubate at 370C for 15 minutes
Blot dry
100 µL diluted conjugate added and incubated at 370C for 15 minutes
Wash six times
100 µL substrate added and incubated at room temperature for thirty
minutes
100 µL stop solution added
Absorbance read at 450 nm (reference 600-700nm) within 30 minutes
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The sensitivity of the kit used is 40pg/ml of HIV1 p24 antigen.  The
kit used has been stated to have a sensitivity of 100% and specificity of
99.71%.
Rapid Assay / Dot Immuno Assay
They are based on immunoconcentration method. HIV antigens both
of HIV 1 and 2 are impregnated on comb shaped solid support. Sample used
is diluted in specimen diluent and then added to the kit.  Patient`s sera
containing HIV antibody binds to the antigen in the kit and get immobilized.
Protein A colloidal gold conjugate which is the signal reagent is then added
to the kit. This protein A attaches to the Fc portion of anti HIV antibodies. A
reddish spot proves the formation of immune complex, which further
confirms the presence of anti HIV antibodies in the test serum.
Procedure
The sera and reagents are to be brought to room temperature before
commencing the test procedure. Once started, the test should be carried out
continuously without break. A positive and negative control should be done
simultaneously.
Two drops of sample diluent is instilled in each well. 100 µL of
sample or control kept in each well.  They are mixed to ensure
homogenization. Place the comb shaped solid support into each well.
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Incubate the comb and sera with signal reagent for ten minutes. The signal
reagent used is colloidal gold protein A. The combs are then placed with
their reactive area facing upwards.
Reactive Sample : Pink or red dot of the same or little lesser colour
intensity as that of positive control.
Non Reactive Sample : No colour development.
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RESULTS
The study was conducted in the Institute of Venereology, Madras
Medical College, Chennai.  200 patients including High Risk groups and
contacts of High Risk groups were enrolled in the study.
Total Number of Patients in the Study Group – 200.
TABLE 1.1: PREVALENCE OF HIV POSITIVITY IN THE
STUDY POPULATION BY FOURTH
GENERATION ELISA
HIV FOURTH
GENERATION ELISA
NUMBER
OF
PATIENTS
PERCENTAGE (%)
NEGATIVE 126 63
             POSITIVE   74 37
             TOTAL 100 100
 FIG 1: HIV POSITIVITY AMONG STUDY GROUP BY
FOURTH GENERATION ELISA
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TABLE 1.2: PREVALENCE OF HIV POSITIVITY IN THE
STUDY POPULATION BY RAPID ASSAY
HIV RAPID ASSAY NUMBER OF
PATIENTS
PERCENTAGE
(%)
NEGATIVE 178 89
              POSITIVE   22 11
              TOTAL 100 100
FIG 2: HIV POSITIVITY AMONG STUDY GROUP BY RAPID
ASSAY
56
TABLE 1.3: PREVALENCE OF HIV AMONG THE VARIOUS
GENDERS IN THE STUDY POPULATION BY
FOURTH GENERATION ELISA
        GENDER NEGATIVE POSITIVE TOTAL
FEMALE 19 (63.3%) 11 (36.7%) 30 (100%)
MALE 97 (61.8%) 60 (38.2%) 157 (100%)
TRANSGENDER 10 (76.9%)  3 (23.1%)   13 (100%)
TOTAL          126 (63%)          74 (37%) 200 (100%)
FIG 3: HIV PREVALENCE AMONG VARIOUS GENDERS BY
FOURTH GENERATION ELISA
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TABLE 1.4: PREVALENCE OF HIV AMONG THE VARIOUS
GENDERS IN THE STUDY POPULATION BY
RAPID ASSAY
GENDER NEGATIVE POSITIVE TOTAL
FEMALE 26 (86.7%) 4 (13.3%) 30 (100%)
MALE 141 (89.8%) 16 (10.2%) 157 (100%)
TRANSGENDER 11 (84.6%) 2 (15.4%) 13 (100%)
TOTAL 178 (89%)        22 (11%) 200 (100%)
FIG 4: HIV PREVALENCE AMONG VARIOUS GENDERS BY
RAPID ASSAY
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TABLE 1.5: HIGH RISK CATEGORISATION IN THE STUDY
GROUP
HIGH RISK CATEGORY NUMBER PERCENTAGE (%)
CSW 9 4.5
SEXUAL ABUSE 1 0.5
HOMOSEXUALS (MSM) 14 7
BISEXUALS 10 0.5
TRANSGENDER 13 6.5
EXPOSURE TO CSW 131 65.5
SPOUSE EXPOSED TO CSW 15 7.5
CONTACT TRACING 7 3.5
FIG 5: HIGH RISK CATEGORISATION AMONG THE STUDY
GROUP
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SOCIODEMOGRAPHIC FEATURES
TABLE 2.1:  PREVALENCE OF HIV AMONG VARIOUS AGE
GROUPS   BY FOURTH GENERATION ELISA
AGE IN
YEARS
NEGATIVE POSITIVE TOTAL
<20 13 (76.5%) 4 (23.5%) 17 (100%)
21 – 30 49 (62.8%) 29 (37.2%) 78 (100%)
31 – 40 23 (47.9%) 25 (52.1%) 48 (100%)
>40 41 (71.9%) 16 (28.1%) 57 (100%)
TOTAL     126 (63%)       74 (37%)      200 (100%)
FIG  6 : PREVALENCE OF HIV IN VARIOUS AGE GROUPS BY
FOURTH GENERATION ELISA
<20         21-30       31 -40     >40
                                                              AGE IN YEARS
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TABLE 2.2: PREVALENCE OF HIV AMONG VARIOUS AGE
GROUPS    BY RAPID ASSAY
AGE IN YEARS NEGATIVE POSITIVE TOTAL
<20 17 (100%)   0 (0%)  17 (100%)
21 – 30  70 (89.7%) 8 (10.3%) 78 (100%)
31 – 40  39 (81.3%) 9 (18.7%) 48 (100%)
>40  52 (91.2%)   5 (8.8%) 57 (100%)
TOTAL 178 (89%) 22 (11%) 100 (100%)
FIG 7: PREVALENCE OF HIV IN VARIOUS AGE GROUPS BY
RAPID ASSAY
                                   <20             21 – 30        31-40         >40
AGE IN YEARS
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TABLE 2.3: PREVALENCE OF HIV AMONG URBAN AND
RURAL POPULATION IN THE STUDY GROUP
BY FOURTH GENERATION ELISA
NEGATIVE POSITIVE TOTAL
RURAL    51(63.8%) 29 (36.3%) 80 (100%)
URBAN     75 (62.5%) 45 (37.5%) 120 (100%)
TOTAL 126 (63%)  74 (37%) 200 (100%)
FIG 8: PREVALENCE OF HIV IN RURAL AND URBAN
POPULATION IN  THE STUDY GROUP BY FOURTH
GENERATION ELISA
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TABLE 2.4: PREVALENCE OF HIV AMONG URBAN AND
RURAL   POPULATION IN THE STUDY GROUP
BY RAPID ASSAY
NEGATIVE POSITIVE TOTAL
RURAL  69 (86.3%)   11 (13.8%)   80 (100%)
URBAN   109 (90.8%) 11 (9.2%) 120 (100%)
TOTAL       178 (89.0%)   22 (11.0%) 200 (100%)
FIG 9: PREVALENCE OF HIV AMONG URBAN AND RURAL
POPULATION IN THE STUDY GROUP BY RAPID
ASSAY
63
TABLE 2.5: HIV POSITIVITY BY FOURTH GENERATION
ELISA   AMONG  PATIENTS WITH DIFFERENT
EDUCATIONAL STATUS
NEGATIVE POSITIVE TOTAL
GRADUATE 27
67.5%
13
32.5%
40
100%
HIGHER
SECONDARY
8
44.4%
10
55.6%
18
100%
HIGH SCHOOL 27
60%
18
40%
45
100%
MIDDLE
SCHOOL
17
70.8%
7
29.2%
24
100%
ILLITERATE 47
64.4%
26
35.6%
73
100%
FIG 10: HIV POSITIVITY BY FOURTH GENERATION ELISA
AMONG PATIENTS WITH DIFFERENT
EDUCATIONAL STATUS
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TABLE 2.6: HIV POSITIVITY BY RAPID ASSAY AMONG
PATIENTS WITH DIFFERENT EDUCATIONAL
STATUS
NEGATIVE POSITIVE TOTAL
GRADUATE 38
95%
2
5%
40
100%
HIGHER
SECONDARY
17
94.4%
1
5.6%
18
100%
HIGH
SCHOOL
40
88.9%
5
11.1%
45
100%
MIDDLE
SCHOOL
22
91.7%
2
8.3%
24
100%
ILLITERATE 61
83.6%
12
16.4%
73
100%
FIG 11: HIV POSITIVITY BY RAPID ASSAY AMONG
PATIENTS WITH DIFFERENT EDUCATIONAL
STATUS
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TABLE 2.7: HIV POSITIVITY BY FOURTH GENERATION
ELISA AMONG VARIOUS OCCUPATIONS
OCCUPATION NEGATIVE POSITIVE TOTAL
COOLEY 59
67.8%
28
32.2%
87
100%
CSW 6
66.7%
3
33.3%
9
100%
HOUSE WIFE 10
62.5%
6
37.5%
16
100%
NIL 3
75.0%
1
25.0%
4
100%
OTHERS 2
50%
2
50%
4
100%
PRIVATE 40
55.6%
32
44.4%
72
100%
PROFESSIONAL 0
0%
1
100%
1
100%
STUDENT 6
85.7%
1
14.3%
7
100%
TOTAL 126
63.0%
74
37.0%
200
100%
FIG 12: HIV POSITIVITY BY FOURTH GENERATION ELISA
AMONG VARIOUS OCCUPATIONS
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TABLE 2.8: HIV POSITIVITY BY RAPID ASSAY  AMONG
VARIOUS OCCUPATIONS
OCCUPATION NEGATIVE POSITIVE TOTAL
COOLEY 7889.7%
9
10.3%
87
100%
CSW 888.9%
1
11.1%
9
100%
HOUSEWIFE 1381.2%
3
18.8%
16
100%
NIL 375%
1
25%
4
100%
OTHERS 375%
1
25%
4
100%
PRIVATE 6691.7%
6
8.3%
72
100%
PROFESSIONAL 00%
1
100%
1
100%
STUDENT 7100%
0
0%
7
100%
TOTAL 17889%
22
11%
200
100%
FIG 13: DISTRIBUTION OF HIV POSITIVITY BY RAPID
ASSAY   AMONG VARIOUS OCCUPATIONS
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TABLE 2.9: HIV PREVALENCE BY FOURTH GENERATION
ELISA IN RELATION TO SEXUAL
ORIENTATION
NEGATIVE POSITIVE TOTAL
HETEROSEXUAL 102
62.6%
61
37.4%
163
100%
HOMOSEXUAL 18
69.2%
8
30.8%
26
100%
BISEXUAL 6
54.5%
5
45.5%
11
100%
TOTAL 126
63%
74
37%
200
100%
FIG 14: HIV PREVALENCE BY FOURTH GENERATION ELISA
IN RELATION TO SEXUAL ORIENTATION
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TABLE 2.10: HIV PREVALENCE BY RAPID ASSAY IN
RELATION TO SEXUAL ORIENTATION
NEGATIVE POSITIVE TOTAL
HETEROSEXUAL 145
89%
18
11%
163
100%
HOMOSEXUAL 23
88.5%
3
11.5%
26
100%
BISEXUAL 10
90.1%
1
9.9%
11
100%
TOTAL 178
89%
22
11%
200
100%
FIG 15: HIV PREVALENCE BY RAPID ASSAY IN RELATION
TO SEXUAL ORIENTATION
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TABLE 2.11: DETECTION OF HIV BY FOURTH GENERATION
ELISA  IN RELATION TO MARITAL STATUS
NEGATIVE POSITIVE TOTAL
MARRIED 64
59.3%
44
40.7%
108
100%
SINGLE 62
67.4%
30
32.6%
92
100%
TOTAL 126
63%
74
37%
200
100%
FIG 16: DETECTION OF HIV BY FOURTH GENERATION
ELISA IN RELATION TO MARITAL STATUS
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TABLE 2.12:  DETECTION OF HIV BY RAPID ASSAY IN
RELATION TO MARITAL STATUS
NEGATIVE POSITIVE TOTAL
MARRIED 96
88.9%
12
11.1%
108
100%
SINGLE 82
89.1%
10
10.9%
92
100%
TOTAL 178
89%
22
11%
200
100%
FIG 17: DETECTION OF HIV BY RAPID ASSAY IN RELATION
TO MARITAL STATUS
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SEXUAL EXPOSURE
TABLE 3.1: HIV POSITIVITY DETECTED BY FOURTH
GENERATION ELISA AMONG PATIENTS WITH
AND WITHOUT EXTRAMARITAL EXPOSURE
EXTRAMARITAL
CONTACT NEGATIVE POSITIVE TOTAL
NIL 10
71.4%
4
28.6%
14
100%
YES 116
62.4%
70
37.6%
186
100%
TOTAL 126
63%
74
37%
200
100%
FIG 18: HIV POSITIVITY DETECTED BY FOURTH
GENERATION ELISA AMONG PATIENTS WITH AND
WITHOUT EXTRAMARITAL EXPOSURE
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TABLE3.2:       HIV POSITIVITY DETECTED BY RAPID ASSAY
AMONG PATIENTS WITH AND WITHOUT
EXTRAMARITAL EXPOSURE
EXTRAMARITAL
CONTACT
NEGATIVE POSITIVE TOTAL
NIL 11
78.6%
3
21.4%
14
100%
YES 167
89.8%
19
10.2%
186
100%
TOTAL 178
89%
22
11%
200
100%
FIG 19: HIV POSITIVITY DETECTED BY FOURTH
GENERATION ELISA AMONG PATIENTS WITH AND
WITHOUT EXTRAMARITAL EXPOSURE
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TABLE 3.3: HIV POSITIVITY BY FOURTH GENERATION
ELISA IN RELATION TO NUMBER OF SEXUAL
PARTNERS
NUMBER OF
PARTNERS NEGATIVE POSITIVE TOTAL
MULTIPLE 4059.7%
27
40.3%
67
100%
NIL 1071.4%
4
28.6%
14
100%
ONE 5466.7%
27
33.3%
81
100%
TWO 2257.9%
16
42.1%
38
100%
TOTAL 12663%
74
37%
200
100%
FIG 20: HIV POSITIVITY BY FOURTH GENERATION ELISA
IN RELATION TO NUMBER OF SEXUAL PARTNERS
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TABLE 3.4: HIV POSITIVITY BY RAPID ASSAY AND
NUMBER OF SEXUAL PARTNERS
NUMBER OF PARTNERS NEGATIVE POSITIVE TOTAL
59 8 67
MULTIPLE 88.1% 11.9% 100%
11 3 14
NIL 78.6% 21.4% 100%
ONE 73 8 81
90.1% 9.9% 100%
TWO 35 3 38
92.1% 7.9% 100%
178 22 200
TOTAL 89% 11% 100%
FIG 21: HIV POSITIVITY BY RAPID ASSAY AND NUMBER OF
SEXUAL PARTNERS
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TABLE 3.5: HIV DETECTION BY FOURTH GENERATION
ELISA IN RELATION TO TIME SINCE LAST
EXPOSURE
TIME SINCE LAST
EXPOSURE
NEGATIVE POSITIVE TOTAL
<2 WEEKS 36
66.7%
18
33.3%
54
100%
2 WEEKS – 2MONTHS 29
53.7%
25
46.3%
54
100%
2 – 6 MONTHS 18
64.3%
10
35.7%
28
100%
>6 MONTHS 33
66%
17
34%
50
100%
NIL EXPOSURE 10
71.4%
4
28.6%
14
100%
FIG 22: HIV DETECTION BY FOURTH GENERATION ELISA
IN RELATION TO TIME SINCE LAST EXPOSURE
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TABLE 3.6 : HIV DETECTION BY RAPID ASSAY IN
RELATION TO TIME SINCE LAST EXPOSURE
TIME SINCE LAST
EXPOSURE
NEGATIVE POSITIVE TOTAL
<2 WEEKS 50
92.6%
4
7.4%
54
100%
2WEEKS –
2MONTHS
50
92.6%
4
7.4%
54
100%
2-6 MONTHS 26
92.9%
2
7.1%
28
100%
>6 MONTHS 41
82%
9
18%
50
100%
NIL 11
78.6%
3
21.4%
14
100%
FIG 23: HIV DETECTION BY RAPID ASSAY IN RELATION TO
TIME SINCE LAST EXPOSURE
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TABLE 3.7: HIV DETECTION BY FOURTH GENERATION
ELISA  IN RELATION TO PATIENT APPROACH
TO VENEREOLOGY DEPARTMENT
NEGATIVE POSITIVE TOTAL
SELF 48
53.3%
42
46.7%
90
100%
NGO 17
73.9%
6
26.1%
23
100%
REFERRAL 57
71.3%
23
28.7%
80
100%
CONTACT
TRACING
4
57.1%
3
42.9%
7
100%
FIG 24: HIV DETECTION BY FOURTH GENERATION ELISA
IN RELATION TO PATIENT APPROACH TO
VENEREOLOGY DEPARTMENT
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FIG 3.8: HIV DETECTION BY RAPID ASSAY IN RELATION TO
PATIENT APPROACH TO VENEREOLOGY
DEPARTMENT
NEGATIVE POSITIVE TOTAL
SELF 78
86.7%
12
13.3%
90
100%
NGO 21
91.3%
2
8.7%
23
100%
REFERRAL 73
91.3%
7
8.7%
80
100%
CONTACT
TRACING
6
85.7%
1
14.3%
7
100%
FIG 25:  HIV DETECTION BY RAPID ASSAY IN RELATION TO
PATIENT APPROACH TO VENEREOLOGY
DEPARTMENT
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TABLE 3.9: HIV DETECTION BY FOURTH GENERATION
ELISA IN PATIENTS WITH COMPLAINTS
COMPLAINTS NEGATIVE POSITIVE TOTAL
NIL 66
65.3%
35
34.7%
101
100%
GENITAL 48
59.3%
33
40.7%
81
100%
NON SPECIFIC 10
62.5%
6
37.5%
16
100%
PARTNER ON ART 1
100%
0
0%
1
100%
SEXUALABUSE 1
100%
0
0%
1
100%
FIG 26: HIV DETECTION BY FOURTH GENERATION ELISA
IN PATIENTS WITH COMPLAINTS
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TABLE 3.10: HIV DETECTION BY RAPID ASSAY IN
PATIENTS WITH COMPLAINTS
COMPLAINTS NEGATIVE POSITIVE TOTAL
NIL 91
90.9%
10
9.1%
101
100%
GENITAL 72
88.9%
9
11.1%
81
100%
NON SPECIFIC 13
81.3%
3
18.8%
16
100%
PARTNER ON ART 1
100%
0
0%
1
100%
SEXUAL ABUSE 1
100%
0
0%
1
100%
FIG 27: HIV DETECTION BY RAPID ASSAY IN PATIENTS
WITH COMPLAINTS
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TABLE 3.11: HIV PREVALENCE BY FOURTH GENERATION
ELISA IN PATIENTS WITH VARIOUS
SEXUALLY TRANSMITTED INFECTIONS
NEGATIVE POSITIVE TOTAL
BACTERIAL
VAGINOSIS
4
66.7%
2
33.3%
6
100%
BALANOPOSTHITIS 6
75%
2
25%
8
100%
EPIDIDYMO
ORCHITIS
0
0%
1
100%
1
100%
DERMATOPHYTOSIS 1
100%
0
0%
1
100%
GENITAL HERPES 2
100%
0
0%
2
100%
GENITAL
MOLLUSCUM
CONTAGIOSUM
1
33.3%
2
66.7%
3
100%
GENITAL SCABIES 2
66.7%
1
33.3%
3
100%
GENITAL WART 2
66.7%
1
33.3%
3
100%
GONOCOCCAL
URETHRITIS
1
100%
0
0%
1
100%
NON GONOCOCCAL
URETHRITIS
3
37.5%
5
62.5%
8
100%
HEPATITIS B 1
100%
0
0%
1
100%
NIL 75
60%
50
40%
125
100%
NON SPECIFIC
GENITAL ULCER
5
83.3%
1
16.7%
6
100%
PERIANAL WART 1
100%
0
0%
1
100%
PROCTITIS 1
100%
0
0%
1
100%
SYPHILIS 20
71.4%
8
28.6%
28
100%
VULVOVAGINAL
CANDIDIASIS
1
50%
1
50%
2
100%
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FIG 28: HIV PREVALENCE BY FOURTH GENERATION ELISA
IN PATIENTS WITH VARIOUS SEXUALLY
TRANSMITTED INFECTIONS
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TABLE 3.12: HIV PREVALENCE BY RAPID ASSAY IN
PATIENTS WITH VARIOUS SEXUALLY
TRANSMITTED INFECTIONS
NEGATIVE POSITIVE TOTAL
BACTERIAL
VAGINOSIS
5
83.3%
1
6.7%
6
100%
BALANOPOSTHITIS 7
87.5%
1
12.5%
8
100%
EPIDIDYMO
ORCHITIS
1
100%
0
0%
1
100%
DERMATOPHYTOSIS 1
100%
0
0%
1
100%
GENITAL HERPES 2
100%
0
0%
2
100%
GENITAL
MOLLUSCUM
CONTAGIOSUM
2
66.7%
1
33.3%
3
100%
GENITAL SCABIES 3
100%
0
0%
3
100%
GENITAL WART 2
66.7%
1
33.3%
3
100%
GONOCOCCAL
URETHRITIS
1
100%
0
0%
1
100%
NON GONOCOCCAL
URETHRITIS
6
75%
2
25%
8
100%
HEPATITIS B 1
100%
0
0%
1
100%
NIL 111
88.8%
14
11.2%
125
100%
NON SPECIFIC
GENITAL ULCER
6
100%
0
0%
6
100%
PERIANAL WART 1
100%
0
0%
1
100%
PROCTITIS 1
100%
0
0%
1
100%
SYPHILIS 27
96.4%
1
3.6%
28
100%
VULVOVAGINAL
CANDIDIASIS
1
50%
1
50%
2
100%
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FIG 29 : HIV PREVALENCE BY RAPID ASSAY IN PATIENTS
WITH VARIOUS SEXUALLY TRANSMITTED
INFECTIONS
85
TABLE 3.13: DETECTION OF HIV BY FOURTH GENERATION
ELISA IN PATIENTS WITH HISTORY OF
PREVIOUS VENEREAL DISEASES
PREVIOUS
VENEREAL
DISEASE
NEGATIVE POSITIVE TOTAL
NIL 118 (62.1%) 72 (37.9%) 190 (100%)
GENITAL HERPES 4 (100%) 0 (0%) 4 (100%)
GENITAL SCABIES 1 (100%) 0 (0%) 1 (0%)
GENITALULCER 3 (60%) 2 (40%) 5 (100%)
FIG 30: DETECTION OF HIV BY FOURTH GENERATION
ELISA IN PATIENTS WITH HISTORY OF PREVIOUS
VENEREAL DISEASES
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TABLE 3.14: DETECTION OF HIV BY RAPID ELISA IN
PATIENTS WITH HISTORY OF PREVIOUS
VENEREAL DISEASES
PREVIOUS
VENEREAL
DISEASE
NEGATIVE POSITIVE TOTAL
NIL 169 (88.9%) 21 (11.1%) 190 (100%)
GENITAL
HERPES
4 (100%) 0 (0%) 4 (100%)
 GENITAL
SCABIES
1 (100%) 0 (0%) 1 (100%)
 GENITAL ULCER 4 (80%) 1 (20%) 5 (100%)
FIG 31: DETECTION OF HIV BY RAPID ELISA IN PATIENTS
WITH HISTORY OF PREVIOUS VENEREAL DISEASES
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OTHER ASSOCIATIONS WITH HIV
TABLE 4.1: DETECTION OF HIV BY FOURTH GENERATION
ELISA IN PATIENTS WITH TUBERCULOSIS
TUBERCULOSIS NEGATIVE POSITIVE TOTAL
NIL 108 (61.4%) 68 (38.6%) 176 (100%)
YES        18 (75%)         6 (25%)   24 (100%)
TOTAL      126 (63%)       74 (37%) 200 (100%)
FIG 32: DETECTION OF HIV BY FOURTH GENERATION
ELISA IN PATIENTS WITH TUBERCULOSIS
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TABLE 4.2: DETECTION OF HIV BY RAPID ELISA IN
PATIENTS  WITH TUBERCULOSIS
TUBERCULOSIS NEGATIVE POSITIVE TOTAL
NIL 157 (89.2%) 19 (10.8%) 176 (100%)
YES   21 (87.5%)   3 (12.5%)   24 (100%)
TOTAL       178 (89%)       22 (11%) 200 (100%)
FIG 33: DETECTION OF HIV BY RAPID ELISA IN PATIENTS
WITH TUBERCULOSIS
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TABLE 4.3: DETECTION OF HIV BY FOURTH GENERATION
ELISA IN INTRAVENOUS DRUG USERS
IVDU NEGATIVE POSITIVE TOTAL
NO 126 (63%) 74 (37%) 200 (100%)
YES 0 (0%) 0 (0%) 0 (0%)
TOTAL 126 (63%) 74 (37%) 200 (100%)
FIG 34: DETECTION OF HIV BY FOURTH GENERATION
ELISA IN INTRAVENOUS DRUG USERS
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TABLE 4.4: DETECTION OF HIV BY RAPID ASSAY IN
INTRAVENOUS DRUG USERS
IVDU NEGATIVE POSITIVE TOTAL
NO 178 (89%) 22 (11%) 200 (100%)
YES 0 (0%) 0 (0%) 0 (0%)
TOTAL 178 (89%) 22 (11%) 200 (100%)
FIG 35: DETECTION OF HIV BY RAPID ASSAY IN
INTRAVENOUS DRUG USERS
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TABLE 4.5: DETECTION OF HIV BY FOURTH GENERATION
ELISA  IN ALCOHOLICS
ALCOHOLISM NEGATIVE POSITIVE TOTAL
NO 72 (68.6%) 33 (31.4%) 105 (100%)
YES 54 (56.8%) 41 (43.2%) 95 (100%)
FIG 36: DETECTION OF HIV BY FOURTH GENERATION
ELISA IN ALCOHOLICS
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TABLE 4.6: DETECTION OF HIV BY RAPID ASSAY IN
ALCOHOLICS
ALCOHOLISM NEGATIVE POSITIVE TOTAL
NO 93 (88.6%) 12 (11.4%) 105 (100%)
YES 85 (89.5%) 10 (10.5%) 95 (100%)
FIG 37: DETECTION OF HIV BY RAPID ASSAY IN
ALCOHOLICS
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TABLE 4.7: DETECTION OF HIV BY FOURTH GENERATION
ELISA IN SMOKERS
SMOKING NEGATIVE POSITIVE TOTAL
NO 81 (66.4%) 41 (33.6%) 122 (100%)
YES 45 (57.7%) 33 (42.3%) 78 (100%)
FIG 38: DETECTION OF HIV BY FOURTH GENERATION
ELISA IN SMOKERS
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TABLE 4.8: DETECTION OF HIV BY RAPID ASSAY IN
SMOKERS
SMOKING NEGATIVE POSITIVE TOTAL
NO 107 (87.7%) 15 (12.3%) 122 (100%)
YES 71 (91%) 7 (9%) 78 (100%)
FIG 39: DETECTION OF HIV BY RAPID ASSAY IN SMOKERS
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DISCUSSION
During the study period, 200 patients (High Risk Group and Contacts
of High Risk Group) were enrolled for Fourth Generation ELISA test along
with Rapid Assay (NACO protocol).
As per the observations in our study, the percentage of patients tested
Positive by Fourth Generation ELISA out of the 200 study group was 37%
and Negative was 63%. The detection rate of HIV Positivity by Rapid Assay
in High Risk Group was 11% ad Negative was 89%.
This result is comparable with the observations by Adeola Folashi de
Afolobi et al (33) who compared  Rapid Assay and ELISA in High Risk
Group in Nigeria. The study population both in terms of High Risk as well
as number was comparable namely 356. They reported a 39.3% detection
rate by Rapid Assay and 50% by ELISA (p24 Ag).
The prevalence of HIV in Nigeria as per 2012 statistics states it that as
the second largest number of HIV incidence worldwide roughly about 3.7%.
Their  High  Risk  Groups  mainly  constitute  CSW,  MSM  and  IV  Drug
Abusers.
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Age
The category with maximum patients were in 20 to 30 years age group
in our study. The second largest category fell in more than 40 years age
group. 39% (78 patients) were in 20 to 30 years category but the category
with maximum tested Positive for HIV by Fourth Generation ELISA was in
31-40 years category (52.1%). The p value was 0.047 which is statistically
significant.
A similar pattern was observed in Rapid Assay with maximum HIV
Positivity of 18.7% in the same age group.
This is in contrast with the observations by Olufemi et  al (40) where
the maximum HIV Positive patients were in their second and third decade
(age group).
Gender
In our study, the maximum population were men constituting 157 in
number of whom 38.2% were tested Positive by Fourth Generation ELISA.
Whereas, among 30 females, 36.7% and  among the 13 Transgenders, 23.1%
were tested Positive by Fourth Generation ELISA.
By Rapid Assay, among the 157 males, 10.2% (16 patients) were HIV
Positive. 13.3% (4 patients) among the 30 females and 15.4% (2 patients)
among the 13 Transgenders were also HIV Positive by Rapid Assay.
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This is in contrast to Maninder Sing Setia et al (38) who studied
focusing only Transgenders and MSMs involved in commercial sex where
68% of Transgenders were tested positive for HIV by Rapid Assay and
ELISA.
Marital Status
108 patients (54%) of our study group (200) were married irrespective
of their sexual orientation. Of these 108 patients, 44 were HIV Positive by
Fourth Generation ELISA (40.7%). Among the 46% (92 patients) unmarried
patients, 32.6% were HIV Positive. This is so because our selection of
patients were patients with other risk factors like CSW exposure or other
STIs.
Rapid Assay detected HIV Positive status in 11.1% of the married
patients and 10.9% among the unmarried patients.
 Pushpa Devi et al (41) reported a 6.5% HIV Positivity in married and
3.19% in unmarried patients.
 The increase in HIV positivity rate in our population is mainly due to
High Risk factors. A higher HIV positive status in married population is
observed in both studies.
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Socioeconomic Status
In our study, 37.5% of urban population and 36.3% of rural patients
were tested HIV Positive by Fourth Generation ELISA. Thus, there was not
much difference in these categories because of the high risk categorization.
Whereas, there was a difference of 1.2 percentage among rural and urban
population.
By Rapid Assay, 13.8% of the rural patients and 9.2% of the urban
patients were HIV Positive. This can be explained by stressing on the fact
that High Risk individuals in an urban set up have more awareness and so
present early to STD department.
UNICEF(42) has also stated the same scenario in its Indian observation
and the reduction in HIV prevalence as the literacy rate improves. Further
more, urban slums constitute a major portion of urban HIV prevalence. This
result is comparable with Kosambiya et al (43) who attributes the increased
HIV prevalence in urban population to swelling of urban slums and
metropolitanisation.
Approach to STD Department
In our study, there was slight dominance of patients who came for self
screening mostly following exposure to commercial sex workers which was
90. Whereas, nearly comparable 80 patients came up as a referral from other
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medical fraternities who presented with various complaints. Interestingly,
46.7% of the self screening patients turned out to be HIV Positive by Fourth
Generation ELISA. Similiarly, 42.9% of  patients with spouse infected by
various  sexually transmitted infections were reported HIV Positive. But,
among the NGO referrals, who were expected to be more at risk only 26.1%
were tested HIV Positive.
A similar trend was observed with Rapid Assay, except for the fact
that the percentages were less. It was observed that these self screening
patients mostly were frequent clients of commercial sex workers and came in
for periodic screening.
This reinforces the increased case detection rates with improving
awareness by counselling as suggested by Rochelle et al (44) in a study
conducted in Massachusetts.
Presenting Complaints
The majority of patients 50.5% (101 patients) came without any
complaints to our STD out patient department. Of which 34.7% (35 patients)
were tested positive for HIV by Fourth Generation ELISA. 81 patients
presented with genital complaints which were in the form of genital itching,
ulcer, urethral discharge, vaginal discharge, genital lesions like genital wart.
A couple of patients presented with difficulty and pain during defaecation,
who on history taking revealed homosexual practice. Out of these 81
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patients, 40.7% (33 patients) were HIV Positive. 16 patients presented with
non specific symptoms like chronic cough, diarrhoea, fever or weight loss,
and came either by self or by referrals. Of them, 6 were HIV Positive
making it the second maximum percentage of HIV Positivity.
Whereas Rapid assay was able to detect HIV Positivity in 18.8%
(3 patients) of  patients with nonspecific symptoms. 11.1% (9 patients)
among the patients with genital complaints were also HIV Positive.
Interestingly, HIV positivity was detected in 9.1% (10 patients) in the sector
of patients who presented without any complaints, but with only recent
exposure to commercial sex worker. This category of patients may be the
ones in the early phase of HIV in whom Rapid Assay lacked expertise.
This was in contrary to a Nigerian study by Olufemi et al(40) with a
similar or comparable study of 218 patients where the foremost presentation
observed was oral thrush. In our study, only one case presented with oral
candidiasis.
Educational Status
In our study, there was not much significant difference in HIV
Positivity among illiterates and literates. This probably might be due to
cultural deviation and westernization among youngsters. Fourth Generation
ELISA detected 35.6% (26 patients) HIV Positives among illiterates.
Whereas Rapid Assay, detected only 16.4% (12 patients) among illiterates.
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This explains the increased awareness and early presentation in case of
educated youth.
Occupation
A maximum proportion of patients were cooley (87 patients) of whom
32.2% (28 patients) were HIV Positive by Fourth Generation ELISA. Of the
72 patients working in private sector which included clerical works, self
employment, delivery boys, 44.4% (32 patients) were HIV Positive by
Fourth Generation ELISA. The next highest category were house wives of
whom 37.5% (6 patients) were HIV Positive. Most of their husbands were
promiscuous with multiple exposure to commercial sex workers. Only one
software professional came for self screening who turned out to be HIV
Positive.
By Rapid Assay, 9 out of the 87 (10.3%) cooleys were HIV Positive.
Among the private sector, 8.3% (6 patients) were HIV Positive by Rapid
Assay. 18.8% (3 patients) of the house wives were also HIV Positive by
Rapid Assay.
This higher HIV prevalence among house wives was comparable to
study conducted by Nitya Vyas et al (45) in 2009 amounting to 33.6%. The
second largest sector in their study were farmers and unskilled workers.
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Sexual Practices
In our study, 81.5% (163 patients) were heterosexuals. Only 5.5% (11
patients) were bisexual, most of them married. 13% (26 patients) of the
study group were homosexuals. The highest percentage of HIV Positives
were in bisexuals nearly 45.5% (5 patients).  A considerable 30.8% (8
patients) of the homosexuals were also HIV Positive by Fourth Generation
ELISA.
In Rapid Assay, there was a higher positivity rate among homosexuals
contributing to 11.5% (3 patients). One bisexual was HIV positive by Rapid
Assay.
Our results have shown an increase in the HIV Positivity among MSM
group. Vivian et al (46) who had conducted a study among 592 Chennai men
way back in 2004, stated a HIV prevalence of 6.5%.
Contact History
In our study, 93% (186 patients) of the patients accepted one or more
extramarital contact or exposure to commercial sex worker. Of these, 37.6%
(70 patients) were HIV Positive by Fourth Generation ELISA. Whereas, in
the remaining 7% (14 patients) who refused extramarital contact, 28.6% (4
patients) were HIV Positive.
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By Rapid Assay, only 10.2% (19 patients) of whom accepted
extramarital contact history were reported HIV Positive. In the contrary
21.4% (3 patients) of those who denied extramarital sexual exposure were
HIV Positive by the same.
A study conducted by Dibua et al (47) quoted that the average age of
first sexual act was around 15 to 20 years in Nigeria. Probably, in Indian set
up the trend though not close still follows this.
Number of contacts
In our study, we observed that 40.3% (27 patients) of patients who had
multiple extramarital exposures were HIV Positive by Fourth Generation
ELISA. 42.1% (16 patients) of those with two sexual exposures to
commercial sex workers were HIV Positive. Whereas 33.3% (27 patients) of
those who had single extramarital exposure to CSW were also HIV Positive
by Fourth Generation ELISA. This almost comparable result in all the above
categories is because we included people with both multiple exposure to
CSW and also those with recent exposure to CSW.
Whereas, Rapid Assay picked up more percentage of HIV Positivity
in the multiple exposure group 11.9% (8 patients) rather than single or two
exposures.
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Wawer M J et al(27) has mentioned that the transmission rate per coital
act increases with the number of exposure as well as the stage of HIV
infection in the Reactive partner. It is stated that in early HIV infection the
transmission rate is 0.0082/coital act whereas after 6 months of
seroconversion the rate drops to 0.0015/ coital act. This further escalates to
0.0028/ coital act just months before death due to established Acquired
Immuno Deficiency Syndrome.
Time period between Extramarital Exposure and Test
In our study, Fourth Generation ELISA was able to identify HIV
Positivity in 46.3% (25 patients) of patients whose last extramarital sexual
exposure was within two weeks and two months.33.3% (18 patients) who
gave last extramarital contact within two weeks were reported HIV Positive
by Fourth Generation ELISA.
Rapid Assay could only pick up HIV Positivity in 7.4% (4 patients) of
the patients whose last extra marital contact fell within two weeks. A similar
percentage of HIV Positivity was noted in the two weeks to two months
category.
This supports the  Fiebig`s HIV Staging and the serological
parameters in each stage as given by Myron et al (21).As per Fiebig`s Staging
of Acute HIV infection, the detection of p24 Ag is from 13 to 28 days since
the day of viral entry into the body. This advantage is picked up by our
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Fourth Generation ELISA which detects both p24 Ag as well as Anti HIV
antibody. Whereas, in Stage 3 of Fiebig`s classification  ELISA positivity is
expected from day 18 to 34 of vial entry into body. This four to eight days
advantage that we get from p24 Ag detection is very crucial, the importance
of which cannot be overemphasized.
There were some patients who refused extra marital sexual exposure
and it was this group which showed more HIV Positivity in Rapid Assay.
This might be due to patient apprehensive of stigmatization, spouse
contribution to infection or due to other modes of spread.
Surgical Procedures in the Study Group:
36.6% (59 patients) of the patients who had never undergone surgery
were HIV Positive by Fourth Generation ELISA. A slightly higher
percentage 38.5% (15 patients) was HIV Positive in the category of patients
who underwent surgeries in the past.
Rapid Assay detected HIV positivity in 11.8% (19 patients) among
patients who had no previous surgeries. Whereas, 7.7% (3 patients) of
patients with history of previous surgeries were HIV Positive by Rapid
Assay.
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William et al (48) refers to Spaulding`s segregation of medical items to
critical, semicritical and non critical and has defined strict sterilization
procedures. In most of our current hospital setups, autoclaving of
instruments and fumigation of operation theatres is scrupulously done. So,
the risk factor involved in surgical procedures is relatively less.
Blood Transfusion
Regarding blood transfusion, only 2 patients gave history of blood
transfusion done 5 years back, of which one was reported to be HIV Positive
by both Fourth Generation ELISA and Rapid Assay.
Jacob John et al (49) quotes NACO`s sentinel surveillance that in 2009,
out of the new HIV infections, less than one percent was through blood and
blood products.
This is consistent with our observation, which reports a 0.5% HIV
positivity both by Fourth Generation ELISA as well as Rapid Assay.
Smoking
In our study, 39% (78 patients) were smokers. Of them, 42.3% (33
patients) were HIV Positive by Fourth Generation ELISA. Whereas,
amongst the non smokers, 33.6% (41 patients) were only HIV Positive by
Fourth Generation ELISA. Whereas, Rapid Assay detected 9% (7 patients)
HIV Positivity among the 78 smokers.
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This observation might be due to the fact that smoking weakens the
mucosal barrier by acting on Human B defensin 2 and Interleukin 8
expression in oral / gingival mucosa which increases the propensity to
acquire infections as mentioned by Mahonanda et al (50). This is true more so
in case of homosexuals with ororeceptive practices, cunnilingus and fellatio.
Alcoholism
In our study, 47.5% (95 patients) of the study group were alcoholics
(taking alcohol more than twice a week). Of them, 43.2% (41 patients) were
HIV Positive by Fourth Generation ELISA. Whereas, among nonalcoholics
the HIV Positive percentage was 31.4% (33 patients).
By Rapid Assay, 10.5% (10 patients) of alcoholics and 11.4% (12
patients) among non alcoholics were HIV Positive.
This is comparable with the observations by Barbara et al (51) who
observed that in alcoholics, lapse of judgement, increased frequency of sex,
high risk behaviours, exposure to commercial sex workers and inconsistent
condom use is much in vogue.
Sexually Transmitted Infections
According to our observations, 62.5% (125 patients) patients had no
Sexually Transmitted Infections. But 40% (50 patients) of them, proved to
be HIV Positive by Fourth Generation ELISA. In our study 37.5% of the
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people had Sexually Transmitted Infections. Syphilis was the commonest
Sexually Transmitted Infection documented in our study. 28.6% (8 patients)
of these Syphilitics were HIV Positive.
8 patients presented with non gonococcal urethritis, of whom 5 were
HIV Positive amounting to 62.5%. Bacterial vaginosis and Candidial
Balanoposthitis were the subsequent groups with six patients each. 33.3% (2
patients) were HIV Positive in each group.
By Rapid Assay, only 11.2% (14 patients) of patients with no
complaints were HIV Positive. 12.5% (1 patient) of Candidal
Balanoposthitis were also Positive by Rapid Assay.
It is comparable with Hawkes et al (52) who reported 22% Sexually
Transmitted Infection in the study group
Also, previous venereal diseases reported in our study group were
genital herpes, genital scabies and genital ulcer. Of them, cases with history
of genital ulcer were 5. Among these 2 patients were HIV Positive by Fourth
Generation ELISA and 1 by Rapid Assay.
Tuberculosis
In our study, out of the 24 patients (12%) who presented with
tuberculosis, 6 patients were HIV Positive by Fourth Generation ELISA
which amounts to 25%.
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Whereas, Rapid Assay could identify only 12.5% (3 patients) of HIV
Positives amongst Tuberculosis patients.
           India, perse is well known for it`s number of tuberculosis patients.
Patients may present with tuberculosis as the first presentation or
tuberculosis reactivation as part of Immune Reconstitution Inflammatory
Syndrome (IRIS).
Sowmya et al (53) reports Tuberculosis - HIV coinfection of 50 to 80%
in SubSaharan Africa and 5 to 24% elsewhere.
Intravenous Drug Abusers
Interestingly, not a single case gave a history of Intravenous Drug
Abuse. This was in contrary to Chandra et al (54) who had studied 180 drug
users in Chennai. It is reported that 69.4% of these patients were HIV
Positive by ELISA and Western Blot.
Most probably, patients in our study group did not disclose drug abuse
history or these sector of patients had different clinical array of presentation.
High Risk Categorisation
The majority of patients who can otherwise be termed as MARG
(Most At Risk Group) were those exposed to CSWs. They contributed to
65.5% (131 patients) of the study group. The next highest group were those,
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whose partners had multiple exposure to CSWs. There were 13
Transgenders in the study. The number of MSMs were 14. There was almost
an equal distribution between Transgenders and MSMs among the
homosexuals. Not a single female in this study, revealed a homosexual
history. There were obvious overlap of categories, like Bisexuals or
Transgenders or those whose  spouse  were exposed to Commercial Sex
Workers and Sexually Transmitted Infections. There were also overlap
between Commercial Sex Workers and patients with Sexually Transmitted
Infections. Considerable number of patients had Multiple Risk factors.
Nitya Vyas et al (38) reported also reported an 86% High Risk sexual
contact leading the risk categories which included Commercial Sex Workers,
exposure to Commercial Sex Workers and Bisexuals.
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SUMMARY
The study group consisted of MARG (Most At Risk Group) - those
exposed to CSWs (65.5%), 13 Transgenders, 14 Homosexuals (MSM), 10
Bisexuals, 9 Commercial Sex Workers, 15 patients with spouse exposed to
CSW, 7 cases of contact tracing and one case of sexual abuse.
 In this study the following observations were made:
1. By Fourth Generation ELISA, out of the 200 High Risk group, the
percentage of patients HIV Positivity was 37% and Negative was
63%.
2. By Rapid Assay, the percentage of HIV Positivity was 11% in the
same study group.
3. The age group highly Positive by Fourth Generation ELISA was 31-
40 years and the positive percentage was 52.1%. The p value was
0.047 which is statistically significant. In the same age group, by
Rapid Assay the Positivity was 18.7%.
4.  36.7% among 30 females, 23.1% among the 13 Transgenders, and
38.2% among 157 men were HIV Positive by Fourth Generation
ELISA.
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5. 30.8% of the homosexuals were HIV Positive by Fourth Generation
ELISA and 11.5% by Rapid Assay. The highest percentage of HIV
Positives were in bisexuals nearly 45.5% by Fourth Generation
ELISA.
6. 37.5% of urban population and 36.3% of rural population were HIV
Positive by Fourth Generation ELISA. There was a difference of 1.2
percentage among rural and urban population.
7. 46.7% of the self screening patients were HIV Positive by Fourth
Generation ELISA. Among the NGO referrals, who were expected to
be more at risk only 26.1% were tested HIV Positive by Fourth
Generation ELISA.
8. 34.7% of the patients with nil complaints were HIV Positive by Fourth
Generation ELISA, 40.7% of the 81 patients with genital complaints
were HIV Positive by Fourth Generation ELISA and among the 16
patients who presented with non - specific complaints - 6 were HIV
Positive by Fourth Generation ELISA.
9. There was not much significant difference in HIV Positivity among
illiterates and literates.
10. A maximum proportion of patients were cooley by occupation. The
next highest category were patients working in private sector and then
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house wives constituting 37.5% amongst which most of their
husbands were promiscuous with multiple exposure to Commercial
Sex Workers.
11.  40.3% of people with multiple extramarital exposures, 42.1% of
patients with two sexual exposures to commercial sex workers and
33.3% of patients with single extramarital exposure to CSW were HIV
Positive by Fourth Generation ELISA.
12. By Fourth Generation ELISA, HIV Positivity was detected in 46.3%
of patients whose last extramarital sexual exposure was within two
weeks and two months. 33.3% who gave last extramarital contact
within two weeks were reported HIV Positive by Fourth Generation
ELISA. By Rapid Assay, only 7.4% of the patients whose last extra
marital contact fell within two weeks were HIV Positive.
13. 43.2% of alcoholics were HIV Positive by Fourth Generation ELISA
and among non - alcoholics the positive percentage was 31.4%.
14. Of the 62.5% patients had no sexually transmitted infections, 40% of
them proved to be HIV Positive by Fourth Generation ELISA.
Syphilis tops the list of STIs in this study.
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15. Among  the Tuberculosis patients, 25% were reported HIV Positive
by Fourth Generation ELISA and  only 12.5% by Rapid Assay.
16. Higher HIV Positive status in married population is maintained in
both Assays in this study.
17. In this study, in most of the categories, the percentage of HIV
Positivity detected by Fourth Generation ELISA was higher than that
detected by Rapid Assay showing that Fourth Generation ELISA is a
more sensitive test than Rapid Assay.
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CONCLUSION
The study group of 200 patients consisted of MARG (Most At Risk
Group) - those exposed to CSWs, Transgenders, Homosexuals, Bisexuals,
Commercial Sex Workers,  patients with spouse exposed to CSW and cases
of contact tracing.
? By Fourth Generation ELISA, out of the 200 High Risk group, the
percentage of HIV Positivity was 37% and Negative was 63%.
? By Rapid Assay, the percentage of HIV Positivity was 11% in the
same study group.
? In this study, in most of the categories, the percentage of HIV
Positivity detected by Fourth Generation ELISA was higher than that
detected by Rapid Assay showing that Fourth Generation ELISA is a
more sensitive test than Rapid Assay.
? A late diagnosis of HIV infection can result in increased transmission,
morbidity, mortality and cost to health care services.
? Hence, Early detection of HIV infection by Fourth Generation ELISA
during the window period prevents transmission from mother to child,
donor to recipient transmission in both blood and organ donations,
transmission by sexual route  and above all improves the chances of
early intervention.
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PROFORMA
Serial no:
STD Op No:
Name:
Age: 1. 11-20
2.21-30
3. 31-40
4. >40
Gender: 1.Male
                          2.Female
                          3.Transgender
Address: 1.Urban
2.Rural
Occupation: 1.Cooley
2. CSW
3. Housewife
 4 . Nil
5. Others
6. Private
7. Professional
                        8.  Student
Educational Status:
1. Illiterate
2. Middle School
3. High School
4. Higher Secondary
5. Graduate
Presenting Complaints:
H/o present illness:
H/o vaginal / urethral discharge:
H/o abdominal pain:
H/o dyspareunia:
H/o genital itching / ulcer /lesions:
H/o pain or difficulty on defaecation: (for Homosexuals)
H/o Chronic fever / diarrhea /weight loss:
Menstrual history
Marital History:
1. Married
2. Single (divorced/ widow/ widower)
Sexual history:
Sexual orientation: 1. Heterosexual
2. Homosexual
3. Bisexual
Last marital contact :
Premarital contact :
Extra marital contact :
Number of extra marital contacts :
Duration since last contact :
Previous STI infections / treatments :
Obstetric history:
Past History:
Tuberculosis :
Diabetes :
Hypertension :
Bronchial asthma :
Previous surgeries :
Blood transfusions :
Jaundice:
Family History:
Personal History:
IV drug abuse:
Aberrant sexual practice:
General examination:
Built :
Pallor :
Jaundice :
Pedal edema :
Generalised lymphadenopathy :
Pulse:
BP:
Systemic examination:
CVS :
RS :
Abdomen :
CNS :
Local examination:
Female:
Any significant inguinal lymphadenopathy:
Inspection:
Vaginal discharge:
Any genital abnormalities:
Per vaginal examination:  Position of cervix and uterus
                                         Cervical motion tenderness
Per speculum examination:
                                        Cervical discharge
                                        Cervical erosion
Skin:
Mucosa:
Bones and Joints:
Male:
Inguinal lymphadenopathy:
Circumcised/ uncircumcised:
Phimosis:
Urethral discharge:
Subprepucial discharge:
Glans penis:
Testis/ scrotum:
Any ulcer/ erosion/ scars:
Skin:
Mucosa:
Bones and Joints:
Investigations
Urine routine:
Urethral/ vaginal / cervical discharge :
                          Grams stain/ wet mount with normal saline  and KOH
Ulcers/erosions: Tzanck smear/ Dark field microscopy/ Grams stain
VDRL for syphilis:
Urine/ pharyngeal swab/ cervical culture for gonococci:
Fourth Generation ELISA for HIV:
Rapid assay for HIV:
Diagnosis:
Clinical:
Microbiological:
PATIENT CONSENT FORM
Title of the study: “A  Study  On  The  Usefulness  Of  Fourth  Generation
ELISA (P24 Antigen and Antibody) For Early
Detection Of HIV Infection In The High Risk Group”.
Name of the participant  :
Name of the principal investigator : Dr. G. Sukanya
Name of the Institution  : Institute of Venereology, Madras
Medical College & Rajiv Gandhi
Government General Hospital,
Chennai – 3.
 Documentation of the informed consent:
  I  ---------------------- have read the information in this form (or it has been
read to me). I was free to ask any questions and they have been answered. I
am over 18 years of age and exercising my free power of choice, hereby
consent to be included as a participant in the study.
1. I have read and understood this consent form and the information
provided to me
2. I have had the consent document explained to me
3. I have been explained about the nature of the study
4.  My rights and responsibilities have been explained to me by the
investigator
5. I agree to co operate with the investigator and I will inform him/her
immediately if I suffer unusual symptoms
6. I have not participated in any research study at any time
7.  I  am  aware  of  the  fact  that  I  can  opt  out  of  the  study  at  any  time
without having to give any reason and this will not affect my future
treatment in this hospital
8. I hereby give permission to the investigator to release the information
obtained from me as a result of participation in this study to the
sponsors, regulatory authorities, Government agencies and
institutional ethics committee. I understand that they are publicly
presented.
9. My identity will be kept confidential if my data are publicly presented.
10. I am aware that if I have any question during the study, I should
contact at one of the addresses listed above. By signing this consent
form I attest that the information given in this document has been
clearly explained to me and apparently understood by me, I will be
given a copy of this consent document.
Participant initials:
For adult participants:
Name and signature/ thumb impression of the participant
(or legal representative if participant is incompetent)
_________             __________________                    -----------------
Name                              Signature                                      Date
Name and signature of impartial witness (required for illiterate patients):
___________           _______________                          _____________
Name                                 Signature                                       Date
Address and contact number of the impartial witness:
Name and signature of the investigator or his representative obtaining
consent:
__________________             _________________               ___________
Name                                          Signature                                          Date
INFORMATION SHEET
Title of the study: “A  Study  On  The  Usefulness  Of  Fourth  Generation
ELISA (P24   Antigen and Antibody) For Early
Detection  Of  HIV  Infection   In  The  High  Risk
Group”.
Name of the participant :
Name of the principal investigator : Dr. G. Sukanya
Name of the Institution : Institute of Venereology, Madras
Medical College & Rajiv Gandhi
Government General Hospital,
Chennai – 3.
? Your specimen (Blood) has been accepted.
? We are conducting a study on HIV detection among patients attending
Rajiv Gandhi Government General Hospital, Chennai and for that
your specimen (blood) may be valuable to us.
? The purpose of this study is to diagnose early cases of HIV infection
with the help of certain special tests.
? We are selecting certain cases and if your specimen is found eligible,
we may be using your specimen to perform extra tests and special
studies which in any way do not affect your final report or
management.
? The privacy of the patients in the research will be maintained
throughout the study. In the event of any publication or presentation
resulting from the research, no personally identifiable information will
be shared.
? Taking part in this study is voluntary. You are free to decide whether
to participate in this study or to withdraw at any time; your decision
will not result in any loss of benefits to which you are otherwise
entitled.
? The results of the special study may be intimated to you at the end of
the study period or during the study if anything is found abnormal
which may aid in the management or treatment.
Signature of  Investigator                                   Signature of Participant
Date:
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1 2 3 1 2 1 3 6 1 1 1 1 1 1 1 2 12 1 1 1 NEGATIVE NEGATIVE 2 5
2 3 3 1 2 1 3 6 1 1 1 1 1 1 1 2 12 1 1 1 POSITIVE POSITIVE 2 5
3 3 1 1 1 2 5 6 2 3 5 2 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 2 6
4 2 1 1 1 1 4 6 2 4 3 1 1 2 2 1 12 1 1 1 NEGATIVE POSITIVE 1 6
5 1 1 1 2 1 4 1 2 4 2 1 1 1 1 2 12 1 1 1 NEGATIVE POSITIVE 2 3
6 3 1 1 2 1 2 1 2 2 2 1 1 2 2 2 12 1 1 1 NEGATIVE POSITIVE 2 3
7 2 1 1 2 1 3 6 2 4 2 1 1 1 1 2 12 1 1 1 NEGATIVE NEGATIVE 2 3
8 3 1 1 3 2 2 1 2 3 2 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 1 6
9 4 1 1 3 3 1 1 2 3 3 2 1 1 2 1 12 1 1 1 NEGATIVE POSITIVE 1 6
10 4 1 1 3 1 5 1 2 2 4 2 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 2 6
11 3 1 1 3 1 1 1 2 2 2 2 1 2 2 1 12 2 1 1 NEGATIVE NEGATIVE 1 6
12 4 1 2 3 2 3 6 2 3 5 1 1 2 2 1 2 2 1 1 NEGATIVE POSITIVE 1 6
13 4 2 1 1 1 1 3 2 2 5 1 1 1 1 1 16 1 1 1 NEGATIVE POSITIVE 1 7
14 3 1 2 1 1 4 6 2 4 3 1 1 2 2 1 12 1 1 1 NEGATIVE POSITIVE 1 6
15 1 3 2 2 1 4 6 2 4 3 2 1 1 1 2 12 1 1 1 NEGATIVE NEGATIVE 2 5
16 1 3 2 2 1 4 6 2 4 5 2 1 1 1 2 12 1 1 1 NEGATIVE POSITIVE 2 5
17 1 3 2 2 1 4 6 2 4 2 2 1 1 1 2 12 1 1 1 NEGATIVE NEGATIVE 2 5
18 2 1 1 1 2 5 6 2 2 2 1 1 2 1 1 13 1 1 1 NEGATIVE NEGATIVE 2 6
19 4 1 2 1 2 3 5 2 4 4 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 1 6
20 3 1 1 3 1 3 6 2 2 5 2 1 2 2 1 12 1 1 1 NEGATIVE POSITIVE 1 6
21 2 1 1 1 1 5 6 2 2 5 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 2 6
22 4 1 2 1 2 4 1 2 4 2 1 1 1 2 1 12 1 1 1 NEGATIVE NEGATIVE 1 6
23 3 1 1 1 2 4 6 2 3 3 1 1 1 1 3 12 1 1 1 NEGATIVE NEGATIVE 1 4
24 3 1 1 1 2 3 6 2 2 3 1 1 2 2 1 13 1 1 1 NEGATIVE NEGATIVE 2 6
25 3 1 2 3 1 2 6 2 2 5 1 1 2 2 1 12 2 1 1 NEGATIVE NEGATIVE 1 6
26 4 1 1 3 1 4 6 2 3 4 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 1 6
Se
ria
l n
o:
A
ge
Se
x
Pl
ac
e
A
pp
ro
ac
h 
to
ST
D
 O
P
C
om
pl
ai
nt
s
Ed
uc
at
io
n
O
cc
up
at
io
n
C
on
ta
ct
s
N
o.
 o
f s
ex
ua
l
pa
rt
ne
rs
Ti
m
e 
si
nc
e 
la
st
co
nt
ac
t
Su
rg
er
y
Tr
an
sf
us
io
n
Sm
ok
in
g
A
lc
oh
ol
Se
xu
al
 o
rie
nt
at
on
ot
he
r S
TI
s
TB PV
D
IV
D
U
R
ap
id
 a
ss
ay
 re
su
lt
4G
 re
su
l
M
ar
ita
l s
ta
tu
s
H
R
G
27 3 1 1 3 1 5 6 2 3 2 1 1 2 2 2 12 1 1 1 NEGATIVE NEGATIVE 1 3
28 2 1 1 2 1 5 6 2 4 2 1 1 1 1 2 12 1 1 1 NEGATIVE NEGATIVE 2 3
29 4 1 2 3 1 1 1 2 2 5 2 1 2 2 1 16 1 1 1 NEGATIVE NEGATIVE 1 6
30 3 2 2 1 1 1 3 2 4 4 1 1 1 1 1 16 1 1 1 NEGATIVE NEGATIVE 1 1
31 2 1 1 1 1 3 6 2 4 2 1 1 1 1 1 12 1 1 1 NEGATIVE POSITIVE 2 6
32 2 1 2 1 1 1 6 2 2 3 1 1 2 2 1 16 2 1 1 NEGATIVE NEGATIVE 1 6
33 2 1 2 1 2 4 6 2 3 4 1 1 1 2 1 13 1 1 1 NEGATIVE POSITIVE 2 6
34 2 1 2 3 2 5 6 2 4 3 2 1 1 2 1 10 1 1 1 NEGATIVE NEGATIVE 1 6
35 2 1 1 1 1 2 6 2 2 3 1 1 2 2 1 12 1 1 1 NEGATIVE POSITIVE 1 6
36 2 1 2 1 1 5 6 2 3 5 1 1 1 1 1 12 1 2 1 NEGATIVE NEGATIVE 2 6
37 3 1 1 1 1 5 6 2 2 3 1 1 1 1 1 12 1 1 1 NEGATIVE POSITIVE 2 6
38 4 1 1 3 1 2 1 2 3 5 1 1 2 2 1 12 1 1 1 NEGATIVE POSITIVE 1 6
39 3 1 1 1 1 3 6 2 4 3 1 1 2 2 1 12 1 1 1 NEGATIVE POSITIVE 2 6
40 4 1 1 1 2 1 1 2 3 3 1 1 2 2 1 12 1 1 1 NEGATIVE POSITIVE 1 6
41 4 1 2 1 2 1 1 2 4 5 2 1 2 2 1 12 1 1 1 NEGATIVE NEGATIVE 1 6
42 2 1 1 1 1 3 6 2 4 2 1 1 2 2 2 12 1 1 1 NEGATIVE NEGATIVE 2 3
43 1 3 1 2 1 3 4 2 4 2 2 1 1 1 2 12 1 1 1 NEGATIVE NEGATIVE 2 5
44 1 1 2 1 2 5 6 2 2 5 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 2 6
45 2 1 1 1 2 1 1 2 2 3 1 1 2 2 1 12 1 1 1 NEGATIVE NEGATIVE 2 6
46 4 1 1 3 2 1 1 1 1 1 1 1 2 2 1 5 1 1 1 NEGATIVE NEGATIVE 2 6
47 3 1 2 3 1 1 1 2 4 5 1 1 2 2 1 12 1 1 1 POSITIVE POSITIVE 1 6
48 4 1 2 3 1 1 1 2 3 5 1 1 2 2 1 12 2 1 1 NEGATIVE NEGATIVE 1 6
49 1 3 1 2 2 3 2 2 4 2 1 1 1 1 2 12 1 1 1 NEGATIVE NEGATIVE 2 5
50 2 1 1 3 2 3 1 1 1 1 1 1 2 2 1 8 1 1 1 NEGATIVE NEGATIVE 2 6
51 3 1 2 1 2 3 1 2 2 5 1 1 1 1 1 12 1 1 1 NEGATIVE POSITIVE 2 6
52 3 1 1 3 1 1 1 2 2 4 1 1 1 1 1 12 2 1 1 NEGATIVE NEGATIVE 1 6
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53 2 1 2 1 2 3 1 2 3 2 1 1 2 2 3 12 1 1 1 NEGATIVE NEGATIVE 1 4
54 2 1 1 2 2 5 4 2 4 3 2 1 2 2 2 4 1 1 1 NEGATIVE NEGATIVE 2 3
55 2 1 2 2 2 5 6 2 4 4 1 1 2 2 2 16 1 1 1 NEGATIVE NEGATIVE 2 3
56 3 1 1 3 1 1 1 2 2 3 1 1 2 2 1 16 1 1 1 NEGATIVE NEGATIVE 1 6
57 4 2 1 3 1 1 1 2 2 2 2 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 1 7
58 2 2 1 3 1 1 2 2 4 2 1 1 1 1 1 1 1 1 1 NEGATIVE NEGATIVE 1 1
59 2 2 1 1 1 5 8 2 2 3 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 2 8
60 4 2 1 4 1 1 3 2 2 5 2 1 1 1 1 16 1 1 1 NEGATIVE NEGATIVE 1 8
61 2 3 1 2 1 1 4 2 4 2 1 1 1 2 2 12 1 1 1 POSITIVE POSITIVE 2 5
62 1 1 2 1 2 4 5 2 2 4 1 1 2 2 1 6 1 1 1 NEGATIVE POSITIVE 2 6
63 2 1 2 1 1 5 6 2 4 3 1 1 1 2 1 12 1 1 1 NEGATIVE POSITIVE 1 6
64 2 1 1 3 2 5 6 2 2 5 1 1 2 2 1 14 1 1 1 NEGATIVE NEGATIVE 2 6
65 2 1 2 1 2 5 6 2 2 4 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 2 6
66 2 1 2 2 2 3 1 2 4 2 1 1 2 2 1 1 1 1 1 NEGATIVE NEGATIVE 1 6
67 4 1 1 1 2 5 6 2 4 3 1 1 2 2 3 10 1 1 1 NEGATIVE POSITIVE 1 4
68 3 1 1 3 1 1 1 2 3 3 2 1 2 2 1 12 1 1 1 NEGATIVE POSITIVE 1 6
69 2 1 2 3 2 1 1 2 2 5 1 1 2 2 1 12 1 1 1 NEGATIVE POSITIVE 1 6
70 2 1 2 1 2 4 1 2 4 5 1 1 2 2 1 16 1 1 1 NEGATIVE NEGATIVE 2 6
71 4 1 1 3 3 1 1 2 4 5 1 1 2 2 1 12 2 1 1 NEGATIVE NEGATIVE 1 6
72 2 1 2 1 1 2 1 2 2 4 1 1 2 2 1 12 1 1 1 NEGATIVE NEGATIVE 2 6
73 2 3 1 2 2 2 1 2 4 5 1 1 1 1 3 12 1 1 1 NEGATIVE NEGATIVE 1 5
74 1 3 1 2 1 3 1 2 4 2 2 1 1 1 2 12 1 1 1 NEGATIVE NEGATIVE 2 5
75 2 3 1 2 1 3 1 2 4 2 2 1 1 2 2 12 1 1 1 NEGATIVE NEGATIVE 2 5
76 2 3 1 2 1 5 8 2 4 2 1 1 1 2 2 12 1 1 1 NEGATIVE NEGATIVE 2 5
77 4 1 1 3 1 1 1 2 2 5 2 1 1 2 1 16 2 1 1 NEGATIVE NEGATIVE 1 6
78 4 1 1 2 1 1 1 2 4 3 1 1 1 1 2 16 1 1 1 NEGATIVE NEGATIVE 2 3
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79 4 1 2 1 1 5 6 2 4 3 1 1 1 2 1 12 1 1 1 NEGATIVE NEGATIVE 1 6
80 3 2 1 1 1 5 6 2 3 4 2 1 1 1 1 12 1 1 1 NEGATIVE POSITIVE 1 7
81 2 1 2 3 3 5 6 1 1 1 1 1 1 1 1 16 1 1 1 NEGATIVE NEGATIVE 2 6
82 2 1 1 1 2 5 6 2 4 2 1 1 1 1 2 12 1 1 1 NEGATIVE POSITIVE 2 3
83 1 2 1 3 1 3 2 2 4 2 1 1 1 1 1 1 1 1 1 NEGATIVE POSITIVE 1 1
84 3 1 2 1 2 1 1 2 4 3 2 1 2 2 1 7 1 1 1 NEGATIVE POSITIVE 1 6
85 3 1 1 1 2 2 6 2 4 3 1 1 2 2 1 12 1 1 1 POSITIVE POSITIVE 1 6
86 3 1 1 1 2 3 6 2 2 5 1 1 1 1 1 12 1 1 1 POSITIVE POSITIVE 1 6
87 4 1 1 1 1 3 6 2 3 5 1 1 2 1 1 12 1 1 1 NEGATIVE NEGATIVE 2 6
88 2 1 2 1 2 5 6 2 2 4 1 1 2 2 1 8 1 1 1 POSITIVE POSITIVE 2 6
89 4 1 2 1 1 3 1 2 3 3 1 1 2 2 1 12 1 1 1 NEGATIVE NEGATIVE 2 6
90 2 1 2 1 1 1 1 2 2 4 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 2 6
91 2 1 1 3 3 2 1 2 2 5 1 1 1 2 1 12 1 1 1 NEGATIVE NEGATIVE 2 6
92 3 1 1 3 3 1 1 2 4 2 1 1 2 2 1 12 1 1 1 POSITIVE POSITIVE 1 6
93 2 1 1 1 1 5 6 2 3 3 1 1 1 1 1 16 1 3 1 NEGATIVE NEGATIVE 1 6
94 4 2 1 3 2 1 3 2 2 5 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 1 7
95 1 1 1 3 1 2 8 1 1 1 1 2 1 1 1 6 1 1 1 NEGATIVE NEGATIVE 2 6
96 3 2 1 1 2 2 3 2 2 2 2 1 1 1 1 16 1 1 1 NEGATIVE NEGATIVE 1 7
97 1 1 1 3 2 3 8 1 1 1 1 1 1 1 1 7 1 1 1 NEGATIVE NEGATIVE 2 6
98 4 1 1 3 1 1 1 2 4 5 1 1 2 2 1 12 1 1 1 NEGATIVE NEGATIVE 1 6
99 4 1 2 3 1 1 1 2 2 5 1 1 1 1 1 2 2 1 1 NEGATIVE NEGATIVE 1 6
100 4 2 1 4 1 1 3 2 2 4 2 2 1 1 1 1 1 1 1 POSITIVE POSITIVE 1 8
101 4 2 1 3 1 1 3 2 2 5 1 1 1 1 1 16 1 1 1 NEGATIVE NEGATIVE 1 7
102 3 1 1 1 2 3 1 2 3 2 1 1 1 1 1 13 1 2 1 NEGATIVE NEGATIVE 1 6
103 3 1 2 1 2 1 1 2 4 3 1 1 2 2 1 12 2 1 1 NEGATIVE POSITIVE 1 6
104 4 1 1 1 2 1 1 2 4 2 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 1 6
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105 3 1 1 2 1 5 6 2 4 2 1 1 1 1 2 12 1 1 1 NEGATIVE NEGATIVE 2 3
106 3 1 2 3 3 5 6 2 3 3 1 1 2 2 1 12 1 1 1 NEGATIVE NEGATIVE 2 6
107 3 1 2 1 1 3 6 2 2 5 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 2 6
108 4 1 1 3 3 1 1 2 2 5 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 1 6
109 2 1 1 1 2 3 6 2 4 2 1 1 1 1 2 12 1 1 1 NEGATIVE POSITIVE 2 3
110 2 1 1 1 2 5 6 2 2 4 1 1 2 2 1 12 1 2 1 NEGATIVE NEGATIVE 2 6
111 2 1 2 1 1 5 6 2 2 2 1 1 2 2 1 12 1 1 1 NEGATIVE POSITIVE 2 6
112 1 2 1 1 5 2 4 2 2 2 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 2 2
113 2 2 2 3 1 1 2 2 4 4 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 1 1
114 4 2 1 3 1 2 3 2 2 3 2 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 1 7
115 2 2 2 3 1 1 2 2 4 2 1 1 1 1 1 12 1 1 1 POSITIVE POSITIVE 1 1
116 4 1 2 1 2 1 1 2 2 3 1 1 1 1 1 2 1 1 1 NEGATIVE NEGATIVE 1 6
117 3 1 1 1 2 3 1 2 2 2 1 1 2 2 1 13 1 1 1 NEGATIVE NEGATIVE 2 6
118 3 2 2 1 2 1 3 2 2 3 2 1 1 1 1 17 1 1 1 POSITIVE POSITIVE 1 7
119 3 2 1 3 1 3 3 2 2 5 2 1 1 1 1 12 1 1 1 POSITIVE POSITIVE 1 7
120 3 1 2 1 2 1 1 2 4 5 1 1 1 1 2 2 1 1 1 POSITIVE POSITIVE 2 3
121 2 1 1 1 2 4 6 2 4 2 1 1 1 1 3 16 1 1 1 NEGATIVE POSITIVE 1 4
122 3 1 2 3 2 1 1 2 3 3 2 1 2 2 1 16 1 1 1 NEGATIVE POSITIVE 1 6
123 2 1 1 1 2 1 1 2 4 2 1 1 1 1 1 5 1 2 1 NEGATIVE NEGATIVE 2 6
124 4 1 1 1 2 1 1 2 4 2 1 1 1 1 1 12 1 1 1 POSITIVE POSITIVE 1 6
125 4 1 2 3 2 1 1 2 2 4 1 1 1 1 1 12 1 1 1 NEGATIVE POSITIVE 1 6
126 4 1 1 3 3 3 6 2 2 4 2 1 1 1 1 12 1 1 1 NEGATIVE POSITIVE 1 6
127 2 1 2 1 1 5 6 2 3 3 1 1 1 1 1 12 1 1 1 NEGATIVE POSITIVE 1 6
128 2 1 2 1 2 5 6 2 2 4 1 1 2 1 1 12 1 1 1 NEGATIVE NEGATIVE 2 6
129 4 1 1 3 2 3 6 2 3 4 2 1 2 2 1 2 1 1 1 NEGATIVE NEGATIVE 1 6
130 4 1 1 1 3 1 1 2 2 5 1 1 1 1 1 12 2 1 1 POSITIVE POSITIVE 1 6
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131 2 1 1 3 1 1 1 2 2 4 1 1 2 2 1 12 1 1 1 NEGATIVE POSITIVE 1 6
132 4 1 2 3 3 1 1 1 1 1 1 1 2 2 1 12 2 1 1 POSITIVE POSITIVE 2 6
133 4 1 1 1 2 3 6 2 2 4 1 1 1 1 1 10 1 1 1 NEGATIVE POSITIVE 1 6
134 2 2 2 3 1 3 2 2 4 2 2 1 1 1 1 12 1 1 1 NEGATIVE POSITIVE 1 1
135 2 2 2 3 1 1 2 2 4 3 1 1 1 1 1 1 1 1 1 NEGATIVE NEGATIVE 1 1
136 2 1 1 2 1 3 6 2 4 3 2 1 1 1 2 16 1 1 1 NEGATIVE NEGATIVE 2 3
137 2 1 2 1 1 3 1 2 2 5 1 1 1 1 1 12 1 1 1 POSITIVE POSITIVE 2 6
138 2 1 2 1 1 5 6 2 2 3 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 2 6
139 4 2 1 4 1 1 3 2 2 5 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 1 8
140 2 1 2 1 2 3 1 2 3 5 1 1 1 2 1 10 1 1 1 POSITIVE POSITIVE 1 6
141 4 1 2 1 2 1 1 2 3 4 1 1 2 2 1 2 1 1 1 NEGATIVE NEGATIVE 1 6
142 2 1 2 3 1 5 6 2 4 3 1 1 1 1 3 12 1 1 1 NEGATIVE NEGATIVE 1 4
143 3 2 1 3 1 1 1 2 2 2 1 1 1 1 1 16 1 1 1 NEGATIVE NEGATIVE 1 7
144 3 1 1 3 2 1 6 2 2 3 1 1 1 2 1 10 1 1 1 POSITIVE POSITIVE 2 6
145 2 1 1 2 2 3 1 2 4 4 1 1 1 2 3 16 1 1 1 NEGATIVE POSITIVE 2 4
146 4 2 2 1 2 1 3 2 2 5 1 1 1 1 1 17 1 1 1 NEGATIVE NEGATIVE 1 7
147 3 1 1 1 2 1 1 1 1 1 1 1 2 2 1 12 1 1 1 NEGATIVE NEGATIVE 2 6
148 4 1 1 3 1 3 1 2 2 5 1 1 2 2 1 12 2 1 1 NEGATIVE NEGATIVE 2 6
149 4 2 1 4 1 1 3 2 2 3 2 1 1 1 1 12 1 1 1 NEGATIVE POSITIVE 1 8
150 2 1 1 1 2 5 6 2 2 4 2 1 2 2 1 12 1 4 1 NEGATIVE NEGATIVE 2 6
151 3 1 2 3 1 2 1 1 1 1 2 1 2 2 1 12 2 1 1 NEGATIVE NEGATIVE 2 6
152 2 1 2 3 1 1 1 2 2 3 1 1 1 2 1 10 2 1 1 NEGATIVE NEGATIVE 1 6
153 2 1 1 4 2 4 6 2 2 3 1 1 1 1 1 12 1 4 1 NEGATIVE POSITIVE 2 6
154 3 1 2 1 2 4 6 2 2 3 1 1 1 1 1 16 2 1 1 NEGATIVE NEGATIVE 2 6
155 2 1 2 1 1 5 7 1 1 1 1 1 1 1 1 6 1 1 1 POSITIVE POSITIVE 2 6
156 3 1 1 1 2 2 1 2 3 2 1 1 2 2 1 12 2 1 1 NEGATIVE POSITIVE 1 6
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157 2 2 2 3 1 1 2 2 4 2 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 2 1
158 3 1 2 3 3 1 1 2 2 5 1 1 2 2 1 12 1 1 1 NEGATIVE POSITIVE 1 6
159 4 1 1 3 1 1 1 2 3 5 1 1 2 2 1 12 2 1 1 NEGATIVE NEGATIVE 1 6
160 4 1 2 1 2 1 1 2 4 5 1 1 2 2 1 12 1 4 1 NEGATIVE NEGATIVE 1 6
161 4 1 1 3 1 1 6 2 3 5 1 1 1 2 1 12 1 1 1 NEGATIVE NEGATIVE 1 6
162 2 1 2 1 1 4 6 2 3 5 1 1 1 1 1 12 1 4 1 POSITIVE POSITIVE 2 6
163 4 1 1 1 2 3 1 2 2 4 1 1 2 1 1 16 1 1 1 NEGATIVE NEGATIVE 1 6
164 2 1 1 1 2 2 1 2 4 3 1 1 2 2 3 16 1 1 1 POSITIVE POSITIVE 2 4
165 2 2 1 3 1 2 3 2 2 2 2 1 1 1 1 12 2 1 1 NEGATIVE NEGATIVE 1 7
166 1 3 1 1 2 1 1 2 4 2 1 1 2 2 2 15 1 4 1 NEGATIVE NEGATIVE 2 5
167 4 1 2 3 2 3 6 2 4 3 1 1 2 2 1 10 2 1 1 NEGATIVE NEGATIVE 1 6
168 2 1 2 1 1 5 6 2 2 2 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 2 6
169 3 2 1 1 1 1 3 2 2 2 2 1 1 1 1 16 1 1 1 NEGATIVE POSITIVE 1 7
170 4 2 1 1 2 1 3 2 2 5 1 1 1 1 1 1 1 1 1 NEGATIVE NEGATIVE 1 7
171 2 2 2 3 1 1 2 2 4 3 1 1 1 1 1 1 1 1 1 NEGATIVE NEGATIVE 2 1
172 4 1 1 4 3 1 6 2 2 5 1 1 1 1 1 16 1 1 1 NEGATIVE NEGATIVE 1 8
173 3 1 2 3 1 2 1 2 2 5 1 1 1 1 1 16 2 1 1 NEGATIVE NEGATIVE 1 6
174 2 1 1 3 1 2 6 2 2 2 1 1 2 2 1 12 1 1 1 NEGATIVE POSITIVE 1 6
175 4 1 2 3 1 1 6 2 3 5 1 1 2 2 1 12 2 1 1 POSITIVE POSITIVE 1 6
176 2 1 1 1 1 3 1 2 4 2 1 1 1 1 3 12 1 1 1 NEGATIVE NEGATIVE 1 4
177 4 1 1 3 3 1 1 2 2 4 2 1 1 2 1 2 1 1 1 NEGATIVE NEGATIVE 2 6
178 2 1 2 3 2 1 1 2 2 2 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 1 6
179 4 1 1 4 4 2 1 2 3 2 1 1 1 2 1 12 1 1 1 NEGATIVE NEGATIVE 1 8
180 4 1 1 3 3 3 6 2 3 2 1 1 2 1 1 12 1 1 1 NEGATIVE NEGATIVE 1 6
181 4 1 2 3 3 1 1 2 2 3 1 1 2 2 1 12 2 1 1 NEGATIVE NEGATIVE 1 6
182 2 1 1 3 2 5 5 2 4 3 1 1 2 2 1 12 1 1 1 NEGATIVE POSITIVE 2 6
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183 2 1 1 1 2 3 1 2 4 3 1 1 1 2 1 12 1 1 1 NEGATIVE POSITIVE 2 6
184 1 1 1 3 1 1 1 2 4 3 1 1 2 2 3 12 1 1 1 NEGATIVE NEGATIVE 2 4
185 4 1 2 1 1 3 1 2 4 3 1 1 2 2 1 12 1 1 1 NEGATIVE POSITIVE 2 6
186 2 1 2 3 2 5 8 1 1 1 1 1 1 2 1 7 1 1 1 NEGATIVE NEGATIVE 2 6
187 3 1 1 1 2 2 1 2 2 2 1 1 1 1 1 13 1 1 1 NEGATIVE NEGATIVE 1 6
188 2 1 1 1 1 5 6 2 3 2 1 1 1 1 3 12 1 1 1 NEGATIVE POSITIVE 2 4
189 1 1 1 3 1 3 8 2 2 3 1 1 1 1 1 12 1 1 1 NEGATIVE NEGATIVE 2 6
190 3 1 1 3 1 1 1 2 2 5 1 1 1 2 1 12 2 1 1 NEGATIVE NEGATIVE 1 6
191 2 1 2 3 1 2 1 2 3 5 1 1 1 1 1 16 1 1 1 NEGATIVE NEGATIVE 1 6
192 4 1 1 3 1 1 1 2 3 2 1 1 2 1 1 12 1 1 1 NEGATIVE NEGATIVE 1 6
193 2 1 2 3 3 3 1 2 3 3 2 1 2 2 1 12 1 1 1 NEGATIVE NEGATIVE 1 6
194 3 1 1 1 2 4 6 2 3 3 2 1 2 2 1 4 1 1 1 NEGATIVE POSITIVE 1 6
195 1 1 2 3 1 4 1 1 1 1 1 1 1 1 1 11 1 1 1 NEGATIVE NEGATIVE 2 6
196 2 1 2 1 2 2 1 2 4 4 1 1 1 2 1 8 1 1 1 NEGATIVE NEGATIVE 2 6
197 2 1 1 1 2 5 8 2 2 2 1 1 2 2 1 16 1 1 1 NEGATIVE POSITIVE 2 6
198 3 2 1 1 2 1 1 2 3 3 1 1 1 1 1 16 1 1 1 NEGATIVE POSITIVE 1 7
199 2 1 2 3 2 2 1 2 2 3 1 1 1 2 1 2 1 1 1 NEGATIVE NEGATIVE 2 6
200 2 1 2 3 2 5 5 1 1 1 1 1 2 2 1 10 1 1 1 NEGATIVE POSITIVE 2 6
MASTER CHART KEY WORDS
GENDER
1 MALE
2 FEMALE
3 TRANSGENDER
PLACE
1 URBAN
2 RURAL
APPROACH TO STD OP
1 SELF
2 NGO
3 REFERRAL
4 CONTACT
TRACING
HIGH RISK GROUP
CATEGORISATION
1 CSW
2 SEXUAL ABUSE
3 HOMOSEXUALS
4 BISEXUALS
5 TRANSGENDER
6 EXPOSURE TO CSW
7 SPOUSE EXPOSED TO
CSW
8 CONTACT TRACING
AGE
1 <20
2 21 -30
3 31-40
4 >40
EDUCATIONAL STATUS
1 ILLITERATE
2 MIDDLE SCHOOL
3 HIGH SCHOOL
4 HIGHER
SECONDARY
5 GRADUATE
OCCUPATION
1 COOLEY
2 CSW
3 HOUSEWIFE
4 NIL
5 OTHERS
6 PRIVATE
7 PROFESSIONAL
8 STUDENT
SEXUAL ORIENTATION
1 HETEROSEXUAL
2 HOMOSEXUAL
3 BISEXUAL
MARITAL STATUS
1 MARRIED
2 SINGLE
EXTRAMARITAL EXPOSURE
1 NIL
2 YES
NUMBER OF SEXUAL
PARTNERS
1 NIL
2 ONE
3 TWO
4 MULTIPLE (>2)
TIME SINCE LAST SEXUAL
EXPOSURE
1 NIL
2 <2 WEEKS
3 2WEEKS -
2MONTHS
4 2 TO  6MONTHS
5 >6MONTHS
PRESENTING COMPLAINTS
1 NIL
2 GENITAL
3 NON SPECIFIC
4 PARTNER ON ART
5 SEXUAL ABUSE
STIs ASSOCIATED
1 BACTERIAL VAGINOSIS
2  BALANOPOSTHITIS
3 EPIDIDYMO ORCHITIS
4 DERMATOPHYTOSIS
5 GENITAL HERPES
6 GENITAL MOLLUSCUM
7 GENITAL SCABIES
8 GENITAL WART
9 GONOCOCCAL
URETHRITIS
10 NONGONOCOCCAL
URETHRITIS
11 HEPATITIS B
12 NIL
13 NON SPECIFIC GENITAL
ULCER
14 PERIANAL WART
15 PROCTITIS
16 SYPHILIS
17 VULVOVAGINAL
CANDIDIASIS
PREVIOUS VENEREAL
DISEASES
1 NIL
2 GENITAL
HERPES
3 GENITAL
SCABIES
4 GENITAL ULCER
TUBERCULOSIS
1 NIL
2 YES
INTRAVENOUS DRUG ABUSE
1 NIL
2 YES
ALCOHOL
1 NIL
2 YES
SMOKING
1 NIL
2 YES
BLOOD TRANSFUSION
1 NIL
2 YES
SURGERY
1 NIL
2 YES
FOURTH GENERATION ELISA KIT
FOURTH GENERATION ELISA
METHODOLOGY
RAPID ASSAY
DOT BLOT ASSAY KIT
BALANOPOSTHITIS IN A HIV POSITIVE
MALE PATIENT
HERPETIC ULCER IN A HIV POSITIVE
MALE PATIENT
HERPETIC ULCER IN A HIV POSITIVE
FEMALE PATIENT
VAGINAL DISCHARGE IN A HIV POSITIVE
FEMALE PATIENT
GENITAL WART IN A HIV POSITIVE
FEMALE PATIENT
